Tyrosine kinases inhibitors and uses thereof

Abstract

To provide tyrosine kinase inhibitors, and a method for suppressing angiogenesis, metastasis, oncogenesis, and / or immune regulation activities.SOLUTION: The present disclosure generally relates to a novel multiple target inhibitor of tyrosine kinases (TK) which can suppress angiogenesis, metastasis, oncogenesis, and / or immune regulation activities by inhibiting TK and have very potent immunomodulatory activity. The present disclosure also relates to a method of using the tyrosine kinase inhibitors, alone or in combination with HDAC inhibitor, for the treatment of cancers, in particular in cancer immunotherapy, by regulating the tumor microenvironment, including reducing tumor hypoxia, reducing lactic acid accumulation, activating CTL, inhibiting the number and activity of immunosuppressive cells, finally obtaining superior anti-cancer benefits and / or producing lasting immune memory.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present disclosure generally relates to novel multi-targeted inhibitors of tyrosine kinases (TKs), which can suppress angiogenesis, metastasis, carcinogenesis, and / or immunomodulatory activity by inhibiting TKs, and have very strong immunomodulatory activity. The present disclosure also relates to methods of using tyrosine kinase inhibitor(s) alone or in combination with HDAC inhibitors for the treatment of cancer, especially in cancer immunotherapy, by modulating the tumor microenvironment, such as reducing tumor hypoxia, reducing lactate accumulation, activating CTLs, suppressing the number and activity of immunosuppressive cells, ultimately obtaining better anti-cancer effects and / or generating durable immune memory. [Background technology]

[0002] TK inhibitors have been widely developed for the treatment of cancer and are classified as targeted therapeutic agents. With the emergence of cancer immunotherapy, immune checkpoint inhibitors (ICIs) have achieved clinical success, opening up a new turning point in cancer treatment. However, as their clinical application continues to expand, these emerging therapeutic ICIs face challenges and their ORRs (objective response rates) are rather low. Therefore, combination drug strategies are required to improve the ORR and enable patients to obtain better therapeutic effects. Summary of the Invention

[0003] Although experts have made every effort to find an efficient combination regimen of ICIs to enhance the therapeutic effect, the results show very limited potential. There is still a strong need to develop combination therapies of anticancer drugs.

[0004] The present disclosure relates to a series of novel structures of multi-targeted inhibitors of tyrosine kinases (TKs).

[0005] In one embodiment, the present disclosure provides a compound of formula (I): [ka] (In the formula: A is -OD or [ka] where the wavy lines represent bond positions; D is H, C 1-4 alkyl or Ar; Ar is [ka] where the dashed lines represent the bond positions; X is N, CH or CR d n is an integer from 0 to 3; Each R d is, when present, independently selected from the group consisting of methyl, NH2, OH, SH, methoxy, dimethylamino, trifluoromethoxy, cyanide, nitro, nitroso, sulfonate, sulfonamido, C1-C6 alkyl, C1-C6 alkyloxy, carboxamido, F, Cl, and Br; R p is selected from the group consisting of H, methyl, NH2, OH, SH, methoxy, dimethylamino, trifluoromethoxy, cyanide, nitro, nitroso, sulfonate, sulfonamido, C1-C6 alkyl, C1-C6 alkyloxy, carboxamido, F, Cl, and Br; L1, L2 are (i) -NH-C(=O)- or (ii) -(C=O)-NH-; L3 and L4 are (i) -NH-C(=O)- or (ii) -(C=O)-NH-. or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

[0006] In one embodiment, the present disclosure provides a compound of formula (II): [ka] (In the formula, D, L1, L2, L3 and L4 have the same meanings as described in formula (I). or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

[0007] In one embodiment, the present disclosure provides a compound of formula (III): [ka] (wherein D, L3 and L4 have the same meanings as described in formula (I).) or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

[0008] In one embodiment, the present disclosure provides a compound of formula (IV): [ka] (wherein D has the same meaning as described in formula (I)). or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

[0009] In one embodiment, the present disclosure provides a method for producing a method for the preparation of a composition comprising: [ka] TIFF2025069098000008.tif222160TIFF2025069098000009.tif37164 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

[0010] In other embodiments, the present disclosure provides pharmaceutical compositions or combinations comprising the compounds described herein.

[0011] In other embodiments, the present disclosure provides a method for inhibiting angiogenesis, metastasis, carcinogenesis and / or immunomodulatory activity in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein.

[0012] In other embodiments, the present disclosure provides a method for treating a disease or condition associated with a tyrosine kinase and / or a tumor or cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 shows the chemical structure and detailed NMR data for Cbo-23.

[0014] [Figure 2A] 2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 2B] 2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 2C] 2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 2D] 2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 2E-1] 2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 2E-2] 2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 2F]2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 2G] 2A-2G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy.

[0015] [Figure 3A] 3A-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 3B] 3B-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 3C] 3A-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 3D] 3A-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 3E-1] 3A-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 3E-2] 3A-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 3F] 3A-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy. [Figure 3G] 3A-3G show the design and results of animal studies for cabozantinib, Cbo-02 and the combination drug for evaluation of therapeutic efficacy.

[0016] [Figure 4A] 4A-4F show the animal study results for cabozantinib, Cbo-22 and the combination drug for evaluating therapeutic efficacy. [Figure 4B]4A-4F show the animal study results for cabozantinib, Cbo-22 and the combination drug for evaluating therapeutic efficacy. [Figure 4C] 4A-4F show the animal study results for cabozantinib, Cbo-22 and the combination drug for evaluating therapeutic efficacy. [Figure 4D-1] 4A-4F show the animal study results for cabozantinib, Cbo-22 and the combination drug for evaluating therapeutic efficacy. [Figure 4D-2] 4A-4F show the animal study results for cabozantinib, Cbo-22 and the combination drug for evaluating therapeutic efficacy. [Figure 4E] 4A-4F show the animal study results for cabozantinib, Cbo-22 and the combination drug for evaluating therapeutic efficacy. [Figure 4F] 4A-4F show the animal study results for cabozantinib, Cbo-22 and the combination drug for evaluating therapeutic efficacy.

[0017] [Figure 5A] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 5B] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 5C] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 5D] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 5E-1] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 5E-2] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 5F] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 5G] 5A-5G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy.

[0018] [Figure 6A] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 6B] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 6C] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 6D] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 6E-1] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 6E-2] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 6F] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy. [Figure 6G] 6A-6G show the design and results of animal studies for cabozantinib, Cbo-23 and the combination drug for evaluation of therapeutic efficacy.

[0019] [Figure 7A]7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. [Figure 7B] 7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. [Figure 7C] 7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. [Figure 7D] 7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. [Figure 7E-1] 7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. [Figure 7E-2] 7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. [Figure 7F] 7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. [Figure 7G] 7A-7G show the design and results of animal studies for zanzarintinib, Cbo-23-k30 and the combination drug for evaluation of therapeutic efficacy. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0020] definition

[0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terms used in the description are for the purpose of describing particular embodiments only and are not intended to be limiting of the disclosure.

[0022] Where a range of values ​​is provided, each intervening value, to the tenth of the unit of the lower limit, is understood to be between the upper and lower limits of that range, unless the context clearly dictates otherwise (e.g., in the case of a group containing a number of carbon atoms, in which case each number of carbon atoms falling within the range is provided), and any other stated or intervening value within that stated range is included within the scope of the disclosure. The upper and lower limits of these smaller ranges may independently be included within the smaller ranges, and are also included within the scope of the disclosure, subject to any specifically excluded limits in the stated range. Where a stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the disclosure.

[0023] As used herein and in the appended claims, the articles "a" and "an" are used to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article, unless the context clearly dictates otherwise. By way of example, "an element" means one element or more than one element.

[0024] The term "and / or" as used in the specification and claims should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjunctive in some cases and disjunctive in other cases. Multiple elements listed with "and / or" should be construed in the same manner, i.e., "one or more" of the elements so conjoined. Other elements other than the elements specifically listed in the "and / or" clause may be optionally present, whether related or unrelated to those elements specifically identified.

[0025] The terms "halo" and "halogen" as used herein refer to an atom selected from fluorine, chlorine, bromine, and iodine.

[0026] The term "alkyl" refers to a straight or branched chain hydrocarbon group consisting solely of carbon and hydrogen atoms, containing no unsaturation, and having one to multiple carbon atoms. In some embodiments, an alkyl contains 1 to 6 carbon atoms (e.g., C1-C6 alkyl), or 1 to 5 carbon atoms (e.g., C1-C5 alkyl). In some embodiments, an alkyl contains 1 to 4 carbon atoms (e.g., C1-C4 alkyl). In other embodiments, an alkyl contains 1 to 3 carbon atoms (e.g., C1-C3 alkyl). In other embodiments, an alkyl contains 1 to 2 carbon atoms (e.g., C1-C2 alkyl). In other embodiments, an alkyl contains 1 carbon atom (e.g., C1 alkyl). In other embodiments, an alkyl contains 2 to 5 carbon atoms (e.g., C2-C5 alkyl). In other embodiments, an alkyl contains 3 to 5 carbon atoms (e.g., C3-C5 alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl). The alkyl is attached to the remainder of the molecule by a single bond. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted with one or more substituents.

[0027] The term "alkoxy" refers to a group attached through an oxygen atom of the formula --O-alkyl, where alkyl is an alkyl chain as defined above.

[0028] The term "cycloalkyl" as used herein denotes a monovalent group derived from a monocyclic or polycyclic saturated or partially unsaturated carbocyclic ring compound. Examples of C3-C8-cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl and cyclooctyl.

[0029] The term "aryl," as used herein, refers to a monocyclic or polycyclic carbocyclic ring system having one or more aromatic rings, fused or non-fused, such as, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl, and the like.

[0030] The term "heteroaryl" as used herein refers to a monocyclic or polycyclic (e.g., bicyclic, or tricyclic or higher) fused or unfused group or ring system having at least one aromatic ring having 5 to 10 ring atoms, of which one ring atom is selected from S, O, and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O, and N, and the remaining ring atoms are carbon. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, quinoxalinyl, and the like.

[0031] The term "heterocycloalkyl," as used herein, refers to a non-aromatic 3-, 4-, 5-, 6-, or 7-membered ring, or a fused or non-fused bicyclic or tricyclic group, in which (i) at least one ring contains 1 to 3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms are optionally oxidized, (iv) the nitrogen heteroatom is optionally quaternized, and (iv) any of the above rings may be fused to a benzene ring. Representative heterocycloalkyl groups include, but are not limited to, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.

[0032] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed by the term "pharmaceutically acceptable salts" refer to non-toxic salts of compounds of the present disclosure, typically prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts of basic compounds of the present disclosure include, but are not limited to, acetate, ascorbate, adipate, alginate, aspirate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, clavulanate, citrate, cyclopentanepropionate, diethylacetate. , digluconate, dihydrochloride, dodecylsulfanate, edetate, edisylate, estolate, esylate, ethanesulfonate, formate, fumarate, gluceptate, glucoheptanoate, gluconate, glutamate, glycerophosphate, glycolyl arsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrabamate, hydrobromide, hydrochloride, 2-hydroxyethanesulfonate, hydroxynaphthate, hydroiodide, iodide, isonicotinate, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methyl nitrate, methyl sulfate, methanesulfonate, mucoate, 2-naphthalenesulfonate, napsylate, nicotinate, nitrate, oleate, oxalate, pamoate Salts include embonate, palmitate, pantothenate, pectinate, persulfate, phosphate / diphosphate, pimelate, phenylpropionate, polygalacturonate, propionate, salicylate, stearate, sulfate, acetate, succinate, tannate, tartrate, theoclate, thiocyanate, tosylate, triethiodide, trifluoroacetate, undeconate, valerate, and the like.Additionally, when a compound of the present disclosure contains an acidic moiety, suitable pharma- ceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases, such as aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganese, manganese mass, potassium, sodium, zinc, and the like. Salts derived from pharma- ceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, dicyclohexylamines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. Also included are basic nitrogen-containing groups which may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl; and diamyl sulfates; long chain halides, e.g., decyl, lauryl, myristyl, stearyl chloride, bromide and iodide, aralkyl halides, such as benzyl and phenethyl bromides, and others.

[0033] The term "subject" includes organisms such as humans, monkeys, cows, sheep, horses, pigs, cattle, goats, dogs, cats, mice, rats, cultured cells, and transgenic species thereof. In a preferred embodiment, the subject is a human.

[0034] The term "administering" includes routes of administration that allow the active ingredients of the present disclosure to perform their intended function.

[0035] The term "treat" or "treatment" refers to a method of reducing the effects of a disease or condition. Treatment can also refer to a method of reducing the underlying cause of the disease or condition itself, rather than just the symptoms. Treatment can be any reduction from native levels, including but not limited to complete ablation of the disease, condition, or symptoms of the disease or condition.

[0036] The terms "prevent," "prevention," or "preventing" refer to the suppression or prevention of symptoms associated with a target disease.

[0037] The term "therapeutically effective amount" refers to an amount of a compound, material, or composition containing a compound of the present disclosure effective to produce a desired therapeutic effect at a reasonable benefit / risk ratio applicable to any medical treatment.

[0038] Tyrosine Kinase (TK) Inhibitor Compounds

[0039] Tyrosine kinase inhibitors are considered to be a successful class of anti-cancer drugs for clinical application. Potential TK targets for inhibition include c-MER, AXL, ROS1, BTK, TYRO3 (RSE), NTRK2 (TRKB), LCK, LYNB, FLT4 (VEGFR3), EPHA2, HCK, FER, FLT3, FGR, FRK (PTK5), RET, KDR (VEGFR2), SRC, c-MET, PDGFRA, CSFIR (FMS), MST1R (RON), LYNA, INSRR (IRR), and TEK (Tie-2). Numerous TK inhibitors have been approved by the US FDA, including TK inhibitors for the treatment of oncology and non-oncology indications. Some TK inhibitors are also believed to have immunomodulatory activity in the tumor microenvironment, but it is difficult to ascertain whether their inhibition of these TKs is closely related to immunomodulation. Many commercially available TK inhibitors (e.g., regorafenib, lenvatinib, and cabozantinib) have been combined with ICIs (such as anti-PD-1 / anti-PD-L1 Abs) in clinical trials, hoping to improve the antitumor therapeutic efficacy of ICIs through the immunomodulatory ability of TK inhibitors. However, most combination regimens have not met expectations or demonstrated primary endpoint efficacy in clinical trials. This also indicates that in order to significantly improve the anticancer efficacy of cancer immunotherapy, it is necessary to overcome the rigidity of ICIs and create new cancer immunotherapy mechanisms with different new drugs used alone or in combination.

[0040] More and more studies have found that the ORR that determines cancer immunotherapy is controlled by the tumor microenvironment. However, the tumor microenvironment is dynamic and complex, and its composition is uncertain as the state of tumor growth changes. Therefore, it is actually very difficult to effectively regulate the tumor microenvironment. The applicant has focused on this research field and made important discoveries. Without being bound by theory, the applicant surprisingly notes that the following tasks may be important to achieve the goal of regulating the tumor microenvironment. The first important task in regulating the tumor microenvironment is to normalize tumor blood vessels. Only the normalization of tumor blood vessels has the potential to reconstruct the tumor microenvironment. This effectively reverses the attraction of a large number of immune suppressive cells (e.g., Treg, TAM, and MDSC) to the tumor microenvironment and promotes the attraction of CTL and NK to the tumor microenvironment to attack the tumor. The second important task is to alleviate the problem of hypoxia in the tumor microenvironment and reduce the expression of HIF-1, which helps CTL to continue to maintain the ability to attack the tumor. The third important task is to effectively overcome the anaerobic respiration that regulates the tumor microenvironment, reduce the synthesis and accumulation of lactic acid, and weaken the continuous maintenance of the acidic environment in the tumor microenvironment, which leads to the activity and survival of CTLs for attacking tumors. The fourth important task is to attract and guide more CTLs that already have the ability to identify tumors into the tumor microenvironment to effectively attack tumors and achieve the benefits of tumor elimination. Among them, increasing antigen presentation is very important to improve the cancer cell recognition ability of CTLs. The last important task is to induce immune memory that the host can generate, so that tumors with the same surface antigens can be eradicated and prevented from recurring, allowing the host to obtain long-term therapeutic effects.

[0041] Thus, the present disclosure relates to a particular class of multikinase inhibitors that can be used in combination with a particular class of HDAC inhibitor(s), where the combination can meet the above-mentioned mechanistic needs, obtain excellent ORR, and generate long-term immune memory for cancer immunotherapy. Surprisingly, the compounds of formula (I) described herein (or formulas (II)-(IV), e.g., Cbo-23 and its derivatives) have been demonstrated to have dual properties of multikinase inhibitor and tumor immune activation through repeated validation in animal studies, and when they are combined with a particular HDAC inhibitor(s), they show excellent cancer immunotherapy activity and generate long-lasting immune memory. In particular, the compounds of formula (I), (II), (III) or (IV), e.g., Cbo-23 and its derivatives, can be further developed into novel drugs for the treatment of tumors and are one component of a new generation of cancer immunotherapy due to their immune-modulating activity in the tumor microenvironment.

[0042] Multi-targeted tyrosine kinase (TK) inhibitors

[0043] As described herein, the compounds of Formula (I), (II), (III) and / or (IV), or pharma- ceutically acceptable salts, hydrates, stereoisomers, solvates or prodrugs thereof, may act as multi-targeted inhibitors of tyrosine kinases.

[0044] In any preceding embodiment, Ar is [ka] and X is N, CH or CR o ;R p is selected from the group consisting of H, NH, and nitro; each R m is independently selected from the group consisting of H, methyl, NH, nitro, nitroso, sulfonate, sulfonamido, C-C alkyl, C-C alkyloxy, carboxamido, F, Br, and Cl; each R ois independently selected from the group consisting of H, methyl, NH, nitro, nitroso, sulfonate, sulfonamido, C1-C6 alkyl, C1-C6 alkyloxy, carboxamido, F, Br, and Cl. [ka] and X is N, CH or CR o ;R p is selected from the group consisting of H, NH, and nitro; each R o is independently selected from the group consisting of H, methyl, NH2, nitro, nitroso, sulfonate, sulfonamido, C1-C6 alkyl, C1-C6 alkyloxy, carboxamido, F, Br, and Cl.

[0045] In any preceding embodiment, Ar is [ka] TIFF2025069098000013.tif68170.

[0046] In one embodiment, in any one of the compounds of formula (I), (II), (III) and / or (IV), L1, L2 are -NH-C(=O)-, and L3, L4 are -NH-C(=O)-. In one embodiment, in any one of the compounds of formula (I), (II), (III) and / or (IV), L1, L2 are -NH-C(=O)-, and L3, L4 are -(C=O)-NH-. In one embodiment, in any one of the compounds of formula (I), (II), (III) and / or (IV), L1, L2 are -(C=O)-NH-, and L3, L4 taken together represent -NH-C(=O)-. In one embodiment, in any one of the compounds of formula (I), (II), (III) and / or (IV), L1, L2 are -(C=O)-NH-, and L3, L4 are -(C=O)-NH-.

[0047] In any preceding embodiment, R pis selected from the group consisting of H, NH2, and nitro (NO2).

[0048] In any preceding embodiment, each R d When present, R is independently selected from the group consisting of methyl, NH, nitro (NO), C-C alkyl, F, Cl, and Br. p is H, n is 1, and R d is located in the meta position relative to the dashed line. In any preceding embodiment, n is 1 or 2, and each R d is located ortho to the dashed line.

[0049] The compounds of formula (I) described herein (or formulas (II)-(IV), e.g., Cbo-23 and its derivatives) are potent multikinase inhibitors, and the mechanism of action of Cbo-23 and its derivatives is similar to that of kinase-specific inhibitors. The compounds of formula (I) described herein (or formulas (II)-(IV), e.g., Cbo-23 and its derivatives) are also multikinase inhibitors with very potent immunomodulatory activity. For example, the results of animal studies show that Cbo-23 and its derivatives, alone or in combination with HDAC inhibitors, exhibited extremely excellent anti-cancer activity, and the combination had particularly excellent anti-cancer therapeutic effects. The excellent anti-cancer effect of this combination is related to the anti-cancer activity of cancer immunotherapy. Without being bound by theory, the mechanism of cancer immunotherapy includes regulating the tumor microenvironment, e.g., reducing tumor hypoxia, reducing lactate accumulation, activating CTLs, suppressing the number and activity of immunosuppressive cells, etc., which leads to better anti-cancer effects through complex interactions and generates persistent immune memory. The compounds disclosed herein, including but not limited to Cbo-23 and its derivatives, may be important components of cancer immunotherapy combinations and have potential in the treatment of cancer.

[0050] The present disclosure encompasses all stereoisomeric forms of the compounds of formulae (I)-(IV), or pharma- ceutically acceptable salts, hydrates, stereoisomers, solvates, or prodrugs thereof. All asymmetric centers present in the compounds of formulae (I)-(IV) may have, independently of one another, the (R) or (S) configuration. When bonds to a chiral carbon are depicted as straight lines in the structural formulae of the present disclosure, it is understood that both (R) and (S) are configurations of the chiral carbon, and thus both enantiomers and mixtures thereof are encompassed in the formula. When a particular configuration is depicted, that enantiomer (either (R) or (S) at that center) is intended. Similarly, when a compound name is described without a chiral designation for a chiral carbon, it is understood that both (R) and (S) are configurations of the chiral carbon, and thus individual enantiomers and mixtures thereof are encompassed in the name.

[0051] The present disclosure includes all possible enantiomers, regioisomers and diastereomers, as well as mixtures of two or more stereoisomers, for example mixtures of enantiomers and / or diastereomers, in all ratios. Enantiomers are therefore subject of the present disclosure in enantiomerically pure form, both as levorotatory enantiomers and as dextrorotatory enantiomers, in the form of racemates, and in the form of mixtures of the two enantiomers in all ratios. In the case of cis / trans isomerism, the present disclosure includes both the cis and trans forms, as well as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, if desired, by separation of the mixtures by conventional methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis, or by stereoselective synthesis. Optionally, derivatization can be carried out before the separation of the stereoisomers. Separation of stereoisomeric mixtures can be performed at an intermediate stage during the synthesis of the compounds of formulas (I)-(IV), or pharma-ceutically acceptable salts, hydrates, stereoisomers, solvates, or prodrugs, or can be performed on the final racemic product. Absolute stereochemistry can be determined by X-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing a stereocenter of known configuration. When compounds of the present disclosure are capable of tautomerization, all individual tautomers as well as mixtures thereof are included within the scope of the present disclosure. The present disclosure includes all such isomers, as well as salts, solvates (including hydrates), and solvated salts of such racemates, enantiomers, diastereomers, tautomers, and mixtures thereof.

[0052] As used herein, the symbols and conventions used in these processes, schemes and examples are consistent with those used in modern scientific literature, e.g., Journal of the American Chemical Society or Journal of Biological Chemistry, regardless of whether a particular abbreviation is specifically defined. Specifically, but not by way of limitation, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams); mL (milliliters); μL (microliters); mM (millimoles); M (micromoles); Hz (Hertz); MHz (Megahertz); mmol (millimoles); hr or hrs (hours); min (minutes); MS (mass spectrometry); ESI (electrospray ionization); TLC (thin layer chromatography); and HPLC (high pressure liquid chromatography). Standard work-up and purification methods known to those skilled in the art can be utilized for all of the following examples. Unless otherwise indicated, all temperatures are expressed in °C (degrees Celsius). All reactions are carried out at room temperature unless otherwise indicated. The synthetic methodology presented herein is intended to illustrate the applicable chemistry through the use of specific examples, and is not indicative of the scope of the present disclosure.

[0053] The compounds of formula (I)-(IV) of the present disclosure are prepared according to general chemical synthesis procedures. Exemplary synthetic routes are shown below. [ka] Step A involves a base and a nucleophilic aromatic substitution reaction. Step B is a reduction to give formula (I). [ka] TIFF2025069098000016.tif68170

[0054] Other suitable modifications of the process, such as using suitable protecting / deprotecting agents for groups sensitive to certain reaction conditions during the synthesis, isolation and purification of intermediates for subsequent reactions, selection of appropriate solvents, etc., can also be introduced by those skilled in the art as necessary. For example, the -OH group of the starting reagent or intermediate of the pathway shown above can be protected prior to reaction (e.g., compound (β) having a protecting group "-OBn" can be derived from an unprotected reagent and used for subsequent reaction with compound (α)), and the resulting (intermediate) product having the protecting group(s) can be deprotected to obtain the subsequent or final product(s) (e.g., compound (γ)), ​​etc.

[0055] Pharmaceutical Compositions / Pharmaceutical Combinations

[0056] In another aspect, the present disclosure provides a pharmaceutical composition or pharmaceutical combination comprising a compound of any of Formulas (I)-(IV), or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate, or prodrug thereof, together with a pharma- ceutically acceptable carrier.

[0057] The pharmaceutical composition or pharmaceutical combination may include one or more second or additional agents. In one embodiment, the second or additional agent is an HDAC inhibitor or an immune checkpoint inhibitor. In a further embodiment, the pharmaceutical composition or pharmaceutical combination includes a compound described herein and an HDAC inhibitor. In a further embodiment, the pharmaceutical composition or pharmaceutical combination includes a compound described herein and an immune checkpoint inhibitor. In a further embodiment, the pharmaceutical composition or pharmaceutical combination includes a compound described herein, an HDAC inhibitor, and an immune checkpoint inhibitor.

[0058] In one embodiment, HDAC inhibitors include but are not limited to chidamide, GNTbm-38(E)-N-(2-aminophenyl)-4-(4-(pyridin-3-yl)but-3-enamido)benzamide, entinostat, mocetinostat, vorinostat, romidepsin, belinostat, panobinostat, zavadinostat, and OKI-179 (bocodepsin).

[0059] In one embodiment, immune checkpoint inhibitors can be used in the pharmaceutical combinations described herein to stimulate the immune system against cancer cells to treat cancer. The immune checkpoint inhibitors are anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies or agents, anti-programmed cell death protein 1 (PD-1) antibodies or agents, anti-programmed death-ligand 1 (PD-L1) antibodies or agents, anti-T-cell immunoglobulin and mucin domain-3 (TIM-3) antibodies or agents, anti-B- and T-lymphocyte attenuator (BTLA) antibodies or agents, anti-V-domain Ig-containing suppressor of T-cell activation (VISTA) antibodies or agents, anti-lymphocyte activation gene-3 (LAG-3) antibodies or agents, KIR (killer cell immunoglobulin-like receptor) inhibitors or antibodies, A2AR (adenosine A2A receptor) inhibitors or antibodies, CD276 inhibitors or antibodies, or VTCN1 inhibitors or antibodies. More preferably, the immune checkpoint inhibitor is pembrolizumab, lambrolizumab, pidilizumab, nivolumab, durvalumab, avelumab, or atezolizumab. Examples of PD-1 or PD-L1 inhibitors include, but are not limited to, humanized antibodies that block human PD-1, such as lambrolizumab (anti-PD-1 Ab, trade name Keytruda) or pidilizumab (anti-PD-1 Ab), BAVENCIO (anti-PD-L1 Ab, avelumab), Imfinzi (anti-PD-L1 Ab, durvalumab), and Tecentriq (anti-PD-L1 Ab, atezolizumab), and fully human antibodies, such as nivolumab (anti-PD-1 Ab, trade name Opdivo) and cemiplimab-rwlc (anti-PD-1 Ab, trade name Libtayo). Other PD-1 inhibitor(s) may include presentations of soluble PD-1 ligands, such as, but not limited to, PD-L2 Fc fusion protein, also known as B7-DC-Ig, or AMP-244, and other PD-1 inhibitors currently under research and / or development for use in therapy.Additionally, immune checkpoint inhibitors can include, but are not limited to, humanized or fully human antibodies that block PD-L1, such as durvalumab and MIH1 (an anti-CD274 (PD-L1, B7-H1) monoclonal antibody), and other PD-L1 inhibitors currently under investigation.

[0060] The additional anti-cancer agent or therapy is any anti-cancer agent or therapy described herein or known in the art. In one embodiment, the additional anti-cancer agent or therapy is chemotherapy or, in particular, platinum-based doublet chemotherapy. In one embodiment, the additional anti-cancer agent is an anti-VEGF or anti-VEGFR antibody or compound. In other embodiments, the anti-cancer agent is a platinum agent (e.g., cisplatin, carboplatin), a mitotic inhibitor (e.g., paclitaxel, albumin-bound paclitaxel, docetaxel, taxotere, dosecado), a fluorinated vinca alkaloid (e.g., vinflunine, jabrol), vinorelbine, vinblastine, etoposide, or pemetrexed, gemcitabine. In one embodiment, the additional anti-cancer agent is 5-flururacil (5-FU). In certain embodiments, the additional anti-cancer agent is any other anti-cancer agent known in the art.

[0061] To prepare the pharmaceutical composition or pharmaceutical combination of the present disclosure, one or more compounds of the present disclosure as active ingredients can be thoroughly mixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, and the carrier can take a wide variety of forms depending on the preparation form desired for administration, for example, oral administration or parenteral administration, such as intramuscular administration. When preparing the composition into oral dosage form, any of the usual pharmaceutical media can be used. Thus, for example, for liquid oral preparations such as suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like; for solid oral preparations such as powders, capsules, caplets, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like. Tablets and capsules are the most advantageous oral dosage unit form due to their ease of administration, in which case a solid pharmaceutical carrier is obviously used. If desired, tablets can be sugar-coated or enteric-coated by standard techniques. For parenteral preparations, the carrier usually comprises sterile water, but other ingredients may be included, for example, for purposes such as aiding solubility or preservation. Injectable suspensions can also be prepared, in which case appropriate liquid carriers, suspending agents, etc. may be utilized. The pharmaceutical composition herein contains the amount of active ingredient required to deliver the above-mentioned effective dose per dosage unit, for example, tablet, capsule, powder, injection, teaspoon, etc.

[0062] Liquid forms into which the novel compositions of the present disclosure may be incorporated for oral administration or administration by injection include aqueous solutions, suitably flavored syrups, aqueous or oily suspensions, and emulsions flavored with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums, such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.

[0063] Tablets and capsules for oral administration are usually provided in unit dosage form and contain conventional excipients such as binding agents, fillers (such as cellulose, mannitol, lactose, etc.), diluents, tabletting agents, lubricants (such as magnesium stearate), surfactants, disintegrants (e.g., polyvinylpyrrolidone and starch derivatives, e.g., sodium starch glycolate), colorants, flavorings, and wetting agents (e.g., sodium lauryl sulfate).

[0064] Oral solid compositions can be prepared by conventional blending, filling or tabletting techniques. By repeating blending procedures, the active principle can be distributed throughout a composition containing a large amount of filler. Such procedures are conventional.

[0065] For parenteral administration, fluid unit dosage forms can be prepared containing the compound and a sterile vehicle. The compound can be suspended or dissolved, depending on the vehicle and concentration. Parenteral solutions are usually prepared by dissolving the compound in a vehicle, sterilizing by filtration, filling a suitable vial, and sealing it. Advantageously, adjuvants such as local anesthetics, preservatives, and buffering agents can also be dissolved in the vehicle. To enhance stability, the composition can be frozen after filling the vial and removing the water under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound can be suspended instead of dissolved in the vehicle, sterilized by exposure to ethylene oxide, and then suspended in a sterile vehicle. Advantageously, a surfactant or wetting agent can be included in the composition to promote uniform distribution of the compound of the present application.

[0066] Pharmaceutical preparations for administration by inhalation can be delivered from an inhaler or nebulizer pressurized packs.

[0067] therapeutic use

[0068] In another aspect, the disclosure provides a method for inhibiting angiogenesis in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein.

[0069] In another aspect, the disclosure provides a method for inhibiting metastasis in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein.

[0070] In another aspect, the present disclosure provides a method for inhibiting carcinogenesis in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein.

[0071] In another aspect, the disclosure provides a method for suppressing immunomodulatory activity in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein.

[0072] In another aspect, the disclosure provides a compound or pharmaceutical composition or pharmaceutical combination described herein for use in a method for inhibiting angiogenesis, metastasis, carcinogenesis and / or immunomodulatory activity in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein. In another aspect, the disclosure provides a use of a compound or pharmaceutical composition or pharmaceutical combination described herein for inhibiting angiogenesis, metastasis, carcinogenesis and / or immunomodulatory activity in a subject in need thereof. In another aspect, the disclosure provides a use of a compound or pharmaceutical composition or pharmaceutical combination described herein in the manufacture of a medicament for inhibiting angiogenesis, metastasis, carcinogenesis and / or immunomodulatory activity in a subject in need thereof.

[0073] In another aspect, the disclosure provides a method for treating a disease or condition associated with a tyrosine kinase in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein.

[0074] In another aspect, the disclosure provides a method for treating a tumor or cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination described herein.

[0075] In another aspect, the disclosure provides a compound, pharmaceutical composition or pharmaceutical combination described herein for use in a method for treating a disease or condition associated with tyrosine kinases or treating a tumor or cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound, pharmaceutical composition or pharmaceutical combination described herein. In another aspect, the disclosure provides a use of a compound, pharmaceutical composition or pharmaceutical combination described herein for treating a disease or condition associated with tyrosine kinases or treating a tumor or cancer in a subject in need thereof. In another aspect, the disclosure provides a use of a compound, pharmaceutical composition or pharmaceutical combination described herein in the manufacture of a medicament for treating a disease or condition associated with tyrosine kinases or treating a tumor or cancer in a subject in need thereof.

[0076] In another aspect, the present disclosure provides a cancer immunotherapy for treating tumor or cancer in a subject in need thereof, by modulating the tumor microenvironment, including, for example, reducing tumor hypoxia, reducing lactate accumulation, activating CTLs, suppressing the number and activity of immunosuppressive cells, ultimately achieving a better anti-cancer effect and / or generating a durable immune memory, comprising administering to the subject an effective amount of a compound, pharmaceutical composition or pharmaceutical combination as described herein.

[0077] In another aspect, the disclosure provides a compound, pharmaceutical composition or pharmaceutical combination as described herein for use in a cancer immunotherapy method for treating a tumor or cancer in a subject in need thereof, comprising administering to the subject an effective amount of a compound, pharmaceutical composition or pharmaceutical combination as described herein. In another aspect, the disclosure provides a use of a compound or pharmaceutical composition or pharmaceutical combination as described herein in a cancer immunotherapy method for treating a tumor or cancer in a subject in need thereof. In another aspect, the disclosure provides a use of a compound, pharmaceutical composition or pharmaceutical combination as described herein in the manufacture of a medicament in a cancer immunotherapy method for treating a tumor or cancer in a subject in need thereof.

[0078] In another aspect, the disclosure provides a method for treating a tumor or cancer with an enhanced objective response rate (ORR) in a subject in need thereof compared to a tumor or cancer treatment based on a pharmaceutical composition or pharmaceutical combination comprising a conventional TK inhibitor(s), comprising administering to the subject an effective amount of a compound or pharmaceutical composition or pharmaceutical combination as described herein.

[0079] In another aspect, the disclosure provides a compound, pharmaceutical composition or pharmaceutical combination described herein for use in a method for treating a tumor or cancer in a subject in need thereof with an increased objective response rate (ORR) compared to a treatment of the tumor or cancer based on a pharmaceutical composition or pharmaceutical combination comprising a conventional TK inhibitor(s), comprising administering to the subject an effective amount of a compound, pharmaceutical composition or pharmaceutical combination described herein. In another aspect, the disclosure provides a use of a compound, pharmaceutical composition or pharmaceutical combination described herein for treating a tumor or cancer in a subject in need thereof with an increased objective response rate (ORR) compared to a treatment of the tumor or cancer based on a pharmaceutical composition or pharmaceutical combination comprising a conventional TK inhibitor. In another aspect, the disclosure provides a use of a compound, pharmaceutical composition or pharmaceutical combination described herein in the manufacture of a medicament for treating a tumor or cancer in a subject in need thereof with an increased objective response rate (ORR) compared to a treatment of the tumor or cancer based on a pharmaceutical composition or pharmaceutical combination comprising a conventional TK inhibitor.

[0080] Examples of cancers that may be treated according to the present disclosure include, but are not limited to, invasive breast cancer, adenocarcinoma, lung cancer (non-small cell carcinoma, squamous cell carcinoma, adenocarcinoma, and large cell lung cancer), liver cancer, colorectal cancer, brain, head and neck cancer (e.g., neuroblastoma / glioblastoma), breast cancer, ovarian cancer, transitional cell carcinoma of the bladder, prostate cancer, oral squamous cell carcinoma, osteosarcoma, adrenal cortical carcinoma, gastrointestinal tumors including colorectal cancer, gallbladder cancer (GBC), and the like. These include biliary tract cancer, bladder cancer, esophageal cancer, gastric cancer, cervical cancer, salivary gland cancer, diarrheal benign neoplasms, ductal carcinoma in situ, paronychia, bile duct cancer, kidney cancer, pancreatic cancer, medulloblastoma, glioblastoma, luminal, HER2-positive and triple-negative breast tumors, hematological malignancies and leukemias (acute myeloid leukemia (AML), B-cell precursor acute lymphoblastic leukemia (ALL), some T-cell ALL, and chronic myeloid leukemia (CML)).

[0081] The compound, or a pharma- ceutically acceptable salt thereof, is administered orally, nasally, transdermally, pulmonary, inhalation, buccal, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally or parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.

[0082] The dosage regimen utilizing the compound is selected according to a variety of factors, such as the type, species, age, weight, sex, and condition of the patient; the severity of the condition being treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt thereof being utilized. An ordinarily skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter, or arrest the progress of the condition.

[0083] Although the disclosure has now been described by way of a written description, those skilled in the art will recognize that the disclosure can be practiced in various embodiments, and that the foregoing description and following examples are intended to be illustrative only and are not limiting of the following claims. EXAMPLES

[0084] Materials and methods for preparing exemplary compounds of the present disclosure are described below.

[0085] All commercially available chemicals and solvents were reagent grade and were used without further purification unless otherwise noted. All reactions were carried out using Merck 60 F 254 Completion was monitored by thin layer chromatography using silica gel glass-backed plates (20 x 20 cm). The resulting chromatograms were visualized under UV illumination (254 nm). 1H NMR spectra were recorded on a Bruker AVANCE III HD 600 MHz spectrometer and chemical shifts were reported in parts per million (ppm, δ). Multiplicities are reported as s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quartet), quin (quintet), sex (sextet), and m (multiplet). Coupling constants (J) are expressed in Hertz. Electrospray mass spectra (ESMS) were recorded as m / z values ​​using a Waters mass spectrometer. The purity of the final compounds was determined using a C 18 The determination was performed on a Waters ACQUITY Arc system using a column (Waters XSelect HSS T3 5 μm, 4.6 mm × 250 mM). Elution was performed using water with 0.1% trifluoroacetic acid as mobile phase A and methanol as mobile phase B. Elution conditions: at 0 min, 90% phase A + 10% phase B; at 6 min, 70% phase A + 30% phase B; at 12 min, 50% phase A + 50% phase B; at 18 min, 10% phase A + 90% phase B; at 23 min, 90% phase A + 10% phase B. The flow rate of the mobile phase was 1 mL / min, the sample injection volume was 20 μL, and the run time was 30 min. Peaks were detected from 210 to 400 nm. The purity of the final compound was found to be >95%.

[0086] Preparation Example

[0087] Example 1 Cbo-02

[0088] Scheme 1. Synthetic scheme for the preparation of Cbo-02 [ka]

[0089] 4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluoroaniline (1)

[0090] A solution of 4-chloro-6,7-dimethoxyquinoline (1 equiv.), 4-amino-2-fluorophenol (1.2-2 equiv.), and NaH (1.2-2.2 equiv.) in DMF was stirred at 100 °C for 10-20 h. The mixture was diluted with EA, washed with water, brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 1 (38% yield) as a beige solid.

[0091] tert-Butyl (1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)carbamoyl)cyclopropyl)carbamate (2)

[0092] To a solution of compound 1 (1 equiv.), 1-((tert-butoxycarbonyl)amino)cyclopropane-1-carboxylic acid (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (2-4 equiv.). The mixture was stirred at room temperature for 1-4 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 2 (97% yield) as a yellow solid.

[0093] 1-Amino-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)cyclopropane-1-carboxamide (3)

[0094] To a solution of compound 2 (1 eq.) in DCM was added TFA (1 eq.). The mixture was stirred at room temperature for 2-8 h. The mixture was diluted with DCM and washed with saturated NaHCO 3(aq) The mixture was neutralized to pH=7 with 10 mL of 1000 ml ...

[0095] N-(1-((4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)carbamoyl)cyclopropyl)-4-fluorobenzamide (Cbo-02)

[0096] To a solution of compound 3 (1 equiv.), 4-fluorobenzoic acid (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DMF, DIPEA (1-3 equiv.) was added. The mixture was stirred at room temperature for 2-4 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give Cbo-02 (78% yield) as a white solid.

[0097] 1 H NMR (600 MHz, DMSO-d6) δ 9.92 (s, 1H), 9.09 (s, 1H), 8.46 (d, J = 5.2 Hz, 1H), 8.04 (dd, J = 8.6, 5.6 Hz, 2H), 7.87 (dd, J = 13.3, 2.3 Hz, 1H), 7.56 (d, J = 7.5 Hz, 1H), 7.52 (s, 1H), 7.41 (t, J = 8.0 Hz, 2H), 7.33 (t, J = 8.8 Hz, 2H), 6.44 (d, J = 5.2 Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 1.51 (q, J = 3.9 Hz, 2H), 1.15 (q, J = 4.0 Hz, 2H). sLCMS (ESI) m / z 520.4 [M+H] + . HPLC purity: 98.88%.

[0098] Example 2 Cbo-03

[0099] Scheme 2. Synthetic scheme for the preparation of Cbo-03 [ka]

[0100] 4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorobenzoic acid (4)

[0101] A solution of 4-chloro-6,7-dimethoxyquinoline (1 equiv.), methyl 3-fluoro-4-hydroxybenzoate (1-1.5 equiv.) and Cs2CO3 (2-3 equiv.) in DMF was stirred at 130-160 °C for 8-20 h. The mixture was diluted with EA and neutralized to pH 6 with 2N HCl. The mixture was washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 4 (13% yield) as a beige solid.

[0102] 4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluoro-N-(1-((4-fluorophenyl)carbamoyl)cyclopropyl)benzamide (Cbo-03)

[0103] To a solution of compound 4 (1 equiv.), 1-amino-N-(4-fluorophenyl)cyclopropane-1-carboxamide (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DMF, DIPEA (2-3 equiv.) was added. The mixture was stirred at room temperature for 1-4 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give Cbo-03 (44% yield) as a white solid.

[0104] 1 H NMR (600 MHz, DMSO-d6) δ 9.71 (s, 1H), 9.19 (s, 1H), 8.52 (d, J = 5.2 Hz, 1H), 8.08 (dd, J = 11.6, 1.8 Hz, 1H), 7.93 (dd, J = 8.4, 1.5 Hz, 1H), 7.63-7.55 (m, 2H), 7.52 (s, 1H), 7.44 (s, 1H), 7.14 (t, J = 8.9 Hz, 2H), 6.49 (d, J = 5.1 Hz, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 1.49 (q, J = 3.9 Hz, 2H), 1.13 (q, J = 3.9 Hz, 2H). LCMS (ESI) m / z 520.4 [M+H]+ . HPLC purity: 98.98%.

[0105] Scheme 3. Synthetic scheme for the preparation of starting material 5 [ka]

[0106] 2-Methoxy-4-nitrophenyl acetate

[0107] To a solution of 2-methoxy-4-nitrophenol (1 equiv.) in DCM was added pyridine (1-1.5 equiv.) and Ac2O (1-1.5 equiv.). The mixture was stirred at room temperature for 2-5 h. The mixture was washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness to give 2-methoxy-4-nitrophenyl acetate (12.3 g, 98%) as a yellow solid.

[0108] 4-Amino-2-methoxyphenyl acetate

[0109] To a solution of 2-methoxy-4-nitrophenyl acetate (1 equiv.) in MeOH, Pd / C (3-5% w / w) was added and the mixture was stirred at room temperature under hydrogen atmosphere for 8-20 h. The mixture was filtered through a Celite pad and the filtrate was concentrated to dryness. The crude product was purified by column chromatography to give 4-amino-2-methoxyphenyl acetate (62% yield) as a yellow oil.

[0110] 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione

[0111] A solution of 2,2-dimethyl-1,3-dioxane-4,6-dione in triethyl orthoformate was stirred for 2-5 h at 80° C. The mixture was concentrated to dryness to give 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (91% yield) as a white solid.

[0112] 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-methoxyphen-yl acetate

[0113] A solution of 4-amino-2-methoxyphenyl acetate (1 equiv.) and 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione (1 equiv.) in EtOH was stirred for 1-4 h at 100° C. The resulting solid was collected by filtration to give 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-methoxyphenyl acetate (88% yield) as a yellow solid.

[0114] 7-Methoxy-4-oxo-1,4-dihydroquinolin-6-yl acetate

[0115] A solution of 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-methoxyphenyl acetate in diphenyl ether was stirred at 160-200 °C for 1-4 h. The resulting solid was collected by filtration and washed with hexane to give 7-methoxy-4-oxo-1,4-dihydroquinolin-6-yl acetate (81% yield) as a brown solid.

[0116] 4-Chloro-7-methoxyquinolin-6-yl acetate

[0117] To a solution of 7-methoxy-4-oxo-1,4-dihydroquinolin-6-yl acetate (1 equiv.) in CHCl3 was added POCl3 (2-6 equiv.) and the mixture was stirred at 60-80 °C for 1-2 h. The mixture was concentrated to dryness. The residue was diluted with EA and washed with saturated NaHCO 3(aq.) The mixture was neutralized to pH 7 with 100 mL of 1000 ml ...

[0118] 4-Chloro-7-methoxyquinolin-6-ol

[0119] To a solution of 4-chloro-7-methoxyquinolin-6-yl acetate (1 equiv.) in EtOH, NaOH (1-1.2 equiv.) was added and the mixture was stirred at 0° C. for 6-16 h. The mixture was acidified to pH 7 with 1N HCl. The resulting solid was collected by filtration to give 4-chloro-7-methoxyquinolin-6-ol (88% yield) as a white solid.

[0120] 6-(Benzyloxy)-4-chloro-7-methoxyquinoline (5)

[0121] To a solution of 4-chloro-7-methoxyquinolin-6-ol (1 equiv.) in DMF was added K2CO3 (2-3 equiv.) and benzyl bromide (1-1.5 equiv.). The mixture was stirred at room temperature for 6-16 h. Water was added to the mixture and the resulting solid was collected by filtration to give compound 5 (81% yield) as a white solid.

[0122] Example 3 Cbo-07

[0123] Scheme 4. Synthetic scheme for the preparation of Cbo-07 [ka]

[0124] 4-((6-(benzyloxy)-7-methoxyquinolin-4-yl)oxy)-3-fluoroaniline (6)

[0125] A solution of compound 5 (1 equiv.), 4-amino-2-fluorophenol (2-4 equiv.), and NaH (2-4 equiv.) in DMF was stirred at 100-130 °C for 8-20 h. The mixture was diluted with EA, washed with water, brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 6 (66% yield) as a beige solid.

[0126] tert-Butyl (1-((4-((6-(benzyloxy)-7-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)carbamoyl)cyclopropyl)carbamate (7)

[0127] To a solution of compound 6, 1-((tert-butoxycarbonyl)amino)cyclopropane-1-carboxylic acid (1 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (1-3 equiv.). The mixture was stirred at room temperature for 2-8 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 7 (89% yield) as a yellow solid.

[0128] 1-Amino-N-(4-((6-(benzyloxy)-7-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)cyclopropane-1-carboxamide (8)

[0129] To a solution of compound 7 (1 equiv.) in DCM was added TFA (3-10 equiv.). The mixture was stirred at room temperature for 2-8 h. The mixture was diluted with DCM and washed with saturated NaHCO 3(aq.) The mixture was neutralized to pH 7 with 100 ml of water. The organic layer was washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness to give compound 8 (99% yield) as a yellow solid.

[0130] N-(1-((4-((6-(benzyloxy)-7-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)carbamoyl)cyclopropyl)-4-fluorobenzamide (9)

[0131] To a solution of compound 8 (1 equiv.), 4-fluorobenzoic acid (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (2-3 equiv.). The mixture was stirred at room temperature for 2-4 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 9 (83% yield) as a white solid.

[0132] 4-Fluoro-N-(1-((3-fluoro-4-((6-hydroxy-7-methoxyquinolin-4-yl)oxy)phenyl)carbamoyl)cyclopropyl)benzamide (Cbo-07)

[0133] A solution of compound 9 (1 equiv.), 1,4-cyclohexadiene (5–10 equiv.) and Pd / C (20% w / w) in EtOH was stirred at 50–100 °C for 1–4 h. The mixture was filtered through a Celite pad and the filtrate was concentrated to dryness. The crude product was purified by column chromatography to give Cbo-07 (95% yield) as a white solid.

[0134] 1 H NMR (600 MHz, DMSO-d6) δ 10.06 (s, 1H), 9.91 (s, 1H), 9.10 (s, 1H), 8.39 (d, J = 5.2 Hz, 1H), 8.03 (dd, J = 8.5, 5.7 Hz, 2H), 7.85 (dd, J = 13.3, 2.1 Hz, 1H), 7.54 (d, J = 9.4 Hz, 1H), 7.47 (s, 1H), 7.39-7.30 (m, 4H), 6.39 (d, J = 5.2 Hz, 1H), 3.94 (s, 3H), 1.50 (q, J = 3.8 Hz, 2H), 1.14 (d, J = 3.9Hz, 2H). LCMS (ESI) m / z 506.2 [M+H] + . HPLC purity: 98.02%.

[0135] Example 4 Cbo-05, 06, 08-10, and 14 and 10a-10f

[0136] Scheme 5. Synthetic scheme for the preparation of Cbo-05, 06, 08-10, and 14. [ka]

[0137] General procedure for the synthesis of 10a-f

[0138] To a solution of Cbo-07 (1 equiv.) and Cs2CO3 (2-3 equiv.) in DMF was added p-fluoronitrobenzene or m-fluoronitrobenzene (1-1.5 equiv.). The mixture was stirred at room temperature for 1-4 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give the desired product. [ka]

[0139] General procedure for the synthesis of Cbo-05, 06, 08, 09, 10, and 14

[0140] To a solution of the nitro adduct (1 equiv.), add Fe (3–6 equiv.) in EtOH / saturated NH4Cl (aq.) was added. The mixture was stirred at 50-100 °C for 1-4 h. The mixture was filtered through a Celite pad. The filtrate was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give the desired product. [ka]

[0141] Yield: 65 mg, 43%. 1H NMR (600 MHz, DMSO-d6) δ 9.86 (s, 1H), 9.03 (s, 1H), 8.47 (d, J = 5.2 Hz, 1H), 8.03 (d, J = 5.8 Hz, 1H), 7.82 (d, J = 13.1 Hz, 1H), 7.51 (d, J = 8.6 Hz, 1H), 7.50 (s, 1H), 7.35-7.28 (m, 3H), 7.24 (s, 1H), 6.86 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 6.40 (d, J = 5.2 Hz, 1H), 5.03 (s, 2H), 4.00 (s, 3H), 1.50 (q, J = 3.7 Hz, 2H), 1.14 (q, J = 3.7 Hz, 2H). LCMS (ESI) m / z 597.3 [M+H] + . HPLC purity: 95.69%.

change

[0142] Yield: 138 mg, 73%. 11H NMR (600 MHz, DMSO-d6) δ 9.88 (s, 1H), 9.04 (s, 1H), 8.54 (d, J = 5.2 Hz, 1H), 8.04 (d, J = 5.8 Hz, 1H), 8.02 (d, J = 5.7 Hz, 1H), 7.84 (dd, J = 13.1, 1.7 Hz, 1H), 7.63 (s, 1H), 7.53 (d, J = 12.4 Hz, 1H), 7.52 (s, 1H) 7.47 (d, J = 2.7 Hz, 1H), 7.37 (t, J = 9.1 Hz, 1H), 7.33 (t, J = 8.8 Hz, 2H), 7.10 (dd, J = 8.6, 2.8 Hz, 1H), 6.85 (d, J = 8.6 Hz, 1H), 6.45 (d, J = 5.2 Hz, 1H), 5.05 (s, 2H), 3.90 (s, 3H), 1.50 (q, J = 3.8 Hz, 2H), 1.14 (q, J = 3.8 Hz, 2H). LCMS (ESI) m / z 598.2 [M+H] + . HPLC purity: 99.16%. [Chemical formula]

[0143] Yield: 86 mg, 53%. 1H NMR (600 MHz, DMSO-d6) δ 9.91 (s, 1H), 9.09 (s, 1H), 8.53 (d, J = 5.2 Hz, 1H), 8.03 (dd, J = 8.7, 5.6 Hz, 2H), 7.84 (dd, J = 13.3, 2.3 Hz, 1H), 7.56 (d, J = 3.4 Hz, 2H), 7.53 (d, J = 8.9 Hz, 1H), 7.38-7.29 (m, 3H), 7.01 (t, J = 7.9 Hz, 1H), 6.44 (d, J = 5.2 Hz, 1H), 6.33 (d, J = 7.2 Hz, 1H), 6.21-6.17 (m, 2H), 5.23 (s, 2H), 3.97 (s, 3H), 1.50 (q, J = 3.9 Hz, 2H), 1.14 (q, J = 4.0 Hz, 2H). LCMS (ESI) m / z 597.3 [M+H] + .HPLC purity: 97.69%.

change

[0144] Yield: 90 mg, 47%. 11H NMR (600 MHz, DMSO-d6) δ 9.87 (s, 1H), 9.06 (s, 1H), 8.46 (d, J = 5.2 Hz, 1H), 8.03 (dd, J = 8.9, 5.6 Hz, 2H), 7.81 (dd, J = 13.3, 2.4 Hz, 1H), 7.53 - 7.49 (m, 2H), 7.35 - 7.28 (m, 3H), 7.05 (s, 1H), 6.78 (d, J = 8.5 Hz, 1H), 6.52 (d, J = 2.6 Hz, 1H), 6.46 (dd, J = 8.5, 2.7 Hz, 1H), 6.39 (d, J = 5.1 Hz, 1H), 4.97 (s, 2H), 4.02 (s, 3H), 1.97 (s, 3H), 1.49 (q, J = 3.9 Hz, 2H), 1.13 (q, J = 4.0 Hz, 2H). LCMS (ESI) m / z 611.3 [M+H] + . HPLC purity: 97.80%.

Chem.

[0145] Yield: 135 mg, 64%. 1 1H NMR (600 MHz, DMSO-d6) δ 9.90 (s, 1H), 9.09 (s, 1H), 8.49 (d, J = 5.2 Hz, 1H), 8.06 - 7.99 (m, 2H), 7.82 (dd, J = 13.3, 2.4 Hz, 1H), 7.52 (s, 1H), 7.51 (d, J = 1.4 Hz, 1H), 7.32 (t, J = 8.8 Hz, 3H), 7.17 (s, 1H), 7.01 (t, J = 9.1 Hz, 1H), 6.52 (dd, J = 13.2, 2.6 Hz, 1H), 6.44 - 6.40 (m, 2H), 5.39 (s, 2H), 4.02 (s, 3H), 1.49 (q, J = 4.0 Hz, 2H), 1.13 (q, J = 4.0 Hz, 2H). LCMS (ESI) m / z 615.3 [M+H] +. HPLC purity: 98.10%. [ka]

[0146] Yield: 226 mg, 91%. 1 H NMR (600 MHz, DMSO-d6) δ 9.90 (s, 1H), 9.10 (s, 1H), 8.51 (d, J = 5.2 Hz, 1H), 8.05-8.00 (m, 2H), 7.83 (dd, J = 13.3, 2.4 Hz, 1H), 7.54 (s, 1H), 7.52 (dd, J = 9.0, 1.4 Hz, 1H), 7.33 (q, J = 9.0 Hz, 3H), 7.18 (s, 1H), 6.44 (d, J = 5.0 Hz, 1H), 6.39 (d, J = 10.6 Hz, 2H), 5.76 (s, 2H), 4.04 (s, 3H), 1.50 (q, J = 4.0 Hz, 2H), 1.14 (q, J = 4.0 Hz, 2H). LCMS (ESI) m / z 633.3 [M+H] + . HPLC purity: 99.34%.

[0147] Example 5 Cbo-20

[0148] Scheme 6. Synthetic scheme for the preparation of Cbo-20 [ka]

[0149] 1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxylic acid (11)

[0150] To a solution of cyclopropane-1,1-dicarboxylic acid (1 equiv.) in THF was added triethylamine (1-1.5 equiv.). The solution was stirred at 0°C for 15 min, after which SOCl2 (1-1.5 equiv.) was added via syringe. After stirring for an additional 15 min, 4-fluoroaniline (1-1.5 equiv.) in THF was added at 0°C and the solution was stirred at room temperature for 8-20 h. The reaction mixture was diluted with NaOH (aq) The mixture was quenched with EA and diluted with EA. The phases were separated and the organic phase was washed with NaOH. (aq) The combined basic extracts were then acidified to pH 2 with HCl and suction filtered to achieve the title compound as a white solid (13% yield).

[0151] 4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluoroaniline (12)

[0152] A solution of 4-chloro-6,7-dimethoxyquinoline (1 equiv.), 4-amino-2-fluorophenol (1.5-4 equiv.), and NaH (1.5-4 equiv.) in DMF was stirred at 70-120 °C for 8-20 h. The mixture was diluted with EA, washed with water, brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 12 (41% yield) as a beige solid.

[0153] N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Cbo-20)

[0154] To a solution of compound 11 (1 equiv.), compound 12 (0.9-1.5 equiv.) and HATU (0.9-1.5 equiv.) in DMF, DIPEA (2-3 equiv.) was added. The mixture was stirred at room temperature for 8-20 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound Cbo-20 (yield 51%) as a white solid.

[0155] 1 H NMR (600 MHz, DMSO-d6) δ10.42 (s, 1H), 10.01 (s, 1H), 8.53 (d, J = 5.2 Hz, 1H), 7.92 (d, J = 13.0 Hz, 1H), 7.65 (dd, J = 8.3, 5.1 Hz, 2H), 7.56 (s, 1H), 7.54 (d, J = 8.9 Hz, 1H), 7.44 (t, J = 8.9 Hz, 2H), 7.15 (t, J = 8.8 Hz, 2H), 6.50 (d, J = 4.5 Hz, 1H), 3.96 (s, 6H), 1.48 (d, J = 6.4 Hz, 4H). LCMS (ESI) m / z 520.73 [M+H]+. HPLC purity: 99.65%.

[0156] Example 6 Cbo-22

[0157] Scheme 7. Synthetic scheme for the preparation of Cbo-22 [ka]

[0158] tert-Butyl (2-(4-chloropicolinamido)propyl)carbamate (13)

[0159] To a solution of 4-chloropicolinic acid (1-1.5 equiv.), tert-butyl (2-aminopropyl) carbamate (1 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (2-5 equiv.). The mixture was stirred at room temperature for 2-8 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 13 (75% yield) as a white solid.

[0160] tert-Butyl (2-(4-(4-amino-2-fluorophenoxy)picolinamido)propyl)carbamate (14)

[0161] A solution of tert-butyl (2-(4-chloropicolinamido)propyl)carbamate (1 equiv.), 4-amino-2-fluorophenol (1-2 equiv.) and Cs2CO3 (2-3 equiv.) in DMF was stirred at 70-120 °C for 2-8 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 14 (65% yield) as a beige solid.

[0162] tert-Butyl (2-(4-(2-fluoro-4(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)picolinamido)propyl)carbamate (15)

[0163] To a solution of compound 11 (1-1.5 equiv.), compound 3 (1 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (1.5-5 equiv.). The mixture was stirred at room temperature for 8-20 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 15 (76% yield) as a white solid.

[0164] N-(4-((2-((1-aminopropan-2-yl)carbamoyl)pyridin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Cbo-22)

[0165] To a solution of compound 4 (1 equiv.) in DCM was added TFA (5-10 equiv.). The mixture was stirred at room temperature for 2-8 h. The mixture was diluted with EA and neutralized to pH=8 with saturated NaHCO3(aq). The mixture was washed with water, brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give Cbo-22 (yield 54%).

[0166] 1H NMR (600 MHz, DMSO-d6) δ 10.38 (brs, 1H), 10.03 (brs, 1H), 8.53 (t, J = 6.5 Hz, 2H), 7.90 (d, J = 13.1 Hz, 1H), 7.64 (dd, J = 8.7, 5.1 Hz, 2H), 7.50 (d, J = 8.7 Hz, 1H), 7.38 (t, J = 9.0 Hz, 1H), 7.35 (d, J = 2.3 Hz, 1H), 7.23 (dd, J = 5.5, 2.5 Hz, 1H), 7.15 (t, J = 8.8 Hz, 2H), 3.90-3.83 (m, 1H), 2.67 (dd, J = 12.6, 5.9 Hz, 1H), 2.60 (dd, J = 12.6, 5.5 Hz, 1H), 1.60(brs, 2H) 1.46 (s, 4H), 1.11 (d, J = 6.6 Hz, 3H). LCMS (ESI) m / z 510.69 [M+H]+. HPLC purity: 99.82%.

[0167] Example 7 Cbo-23

[0168] Scheme 8. Synthetic scheme for the preparation of Cbo-23 [ka]

[0169] 4-((6-(benzyloxy)-7-methoxyquinolin-4-yl)oxy)-3-fluoroaniline (16)

[0170] To a solution of 6-(benzyloxy)-4-chloro-7-methoxyquinoline (1 equiv.), 4-amino-2-fluorophenol (2–5 equiv.) in DMF, NaH (2–5 equiv.) was added and the mixture was stirred at 70–120 °C for 16–30 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 16 (27% yield) as a beige solid.

[0171] N-(4-((6-(benzyloxy)-7-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (17)

[0172] To a solution of compound 16 (1 equiv.), 1-((4-fluorophenyl)carbamoyl)-cyclopropane-1-carboxylic acid (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (2-3 equiv.). The mixture was stirred at room temperature for 10 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 17 (82% yield) as a white solid.

[0173] N-(3-fluoro-4-((6-hydroxy-7-methoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (18)

[0174] To a solution of compound 17 (1 equiv.), 1,4-cyclohexadiene (5–10 equiv.) in EtOH (30 mL), Pd / C (10–40% w / w) was added and the mixture was stirred at 50–100 °C for 1–6 h. The mixture was filtered through a Celite pad and the filtrate was concentrated to dryness. The crude product was purified by column chromatography to give 18 (99% yield) as a white solid.

[0175] N-(3-fluoro-4-((6-(2-fluoro-4-nitrophenoxy)-7-methoxyquinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (19)

[0176] To a solution of compound 18 (1 equiv.) and Cs2CO3 (2-3 equiv.) in DMF was added 1,2-difluoro-4-nitrobenzene (1-1.5 equiv.). The mixture was stirred at room temperature for 1-4 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 19 (75% yield) as a pink solid.

[0177] N-(4-((6-(4-amino-2-fluorophenoxy)-7-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Cbo-23)

[0178] A solution of compound 19 (1 equiv.) and Fe (3–6 equiv.) in EtOH was diluted with saturated NH (aq.) was added. The mixture was stirred at 50–100 °C for 1–6 h. The mixture was filtered through a Celite pad. The filtrate was diluted with EA, washed with water, brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give Cbo-23 (yield 83%) as a pink solid.

[0179] 1H NMR (600 MHz, DMSO-d6) δ 10.35 (s, 1H), 10.00 (s, 1H), 8.50 (d, J = 5.2 Hz, 1H), 7.85 (d, J = 13.0 Hz, 1H), 7.63 (dd, J = 8.8, 5.1 Hz, 2H), 7.53 (s, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.35 (t, J = 9.0 Hz, 1H), 7.19 (s, 1H), 7.15 (t, J = 8.9 Hz, 2H), 7.02 (t, J = 9.0 Hz, 1H), 6.53 (dd, J = 13.2, 2.3 Hz, 1H), 6.43 (dd, J = 8.7, 2.1 Hz, 1H), 6.39 (d, J = 5.2 Hz, 1H), 5.40 (s, 2H), 4.02 (s, 3H), 1.49-1.44 (m, 4H). LCMS (ESI) m / z 615.74 [M+H] + . HPLC purity: 98.41%. Detailed NMR data for Cbo-23 can be found in Figure 1 and Table 1.

[0180] Example 8 Cbo-24

[0181] Scheme 9. Synthetic scheme for the preparation of Cbo-24 [ka]

[0182] Methyl 4-(2-fluoro-4-nitrophenoxy)-7-methoxyquinoline-6-carboxylate (20)

[0183] A solution of methyl 4-chloro-7-methoxyquinoline-6-carboxylate (1 equiv.), 2-fluoro-4-nitrophenol (1.5–3 equiv.) in chlorobenzene was stirred at 120–200 °C for 8–16 h. The mixture was diluted with EA and diluted with 10% NaOH. (aq.)The mixture was washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 20 (yield 95%) as a yellow solid.

[0184] Methyl 4-(4-amino-2-fluorophenoxy)-7-methoxyquinoline-6-carboxylate (21)

[0185] To a solution of compound 20 (1 equiv.) in MeOH was added Pd(OH)2 (40% w / w). The mixture was stirred at room temperature under H2 for 8-20 h. The mixture was filtered through a Celite pad and the filtrate was concentrated to dryness to give compound 21 (68% yield) as a yellow solid.

[0186] Methyl 4-(2-fluoro-4(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)-7-methoxyquinoline-6-carboxylate (22)

[0187] To a solution of compound 21 (1 equiv.), 1-((4-fluorophenyl)carbamoyl)-cyclopropane-1-carboxylic acid (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (2-3 equiv.). The mixture was stirred at room temperature for 8-20 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 22 (99% yield) as a white solid.

[0188] 4-(2-fluoro-4(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)-7-methoxyquinoline-6-carboxylic acid (23)

[0189] To a solution of 22 (1 equiv.) in THF was added LiOH (2-5 equiv.) and the mixture was stirred at room temperature for 1-4 h. The mixture was concentrated to remove THF. The aqueous solution was washed with 1N HCl. (aq.)The mixture was acidified to pH 3. The resulting solid was filtered to give compound 23 (84% yield) as a white solid.

[0190] tert-Butyl (2-(4-(2-fluoro-4-(1-((4-fluorophenyl)carbamoyl)cyclopropane-1-carboxamido)phenoxy)-7-methoxyquinoline-6-carboxamido)propyl)carbamate (24)

[0191] To a solution of compound 23 (1 equiv.), tert-butyl (2-aminopropyl) carbamate (1-1.5 equiv.) and HATU (1-1.5 equiv.) in DMF was added DIPEA (2-3 equiv.). The mixture was stirred at room temperature for 1-4 h. The mixture was diluted with EA, washed with water, brine and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give compound 24 (98% yield) as a yellow solid.

[0192] O-Phenyl-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Cbo-24)

[0193] To a solution of compound 24 (1 equiv.) in DCM was added TFA (5-10 equiv.). The mixture was stirred at room temperature for 8-20 h. The mixture was diluted with EA and saturated NaHCO 3(aq) The mixture was neutralized to pH = 8 with 50 ml of 10 ...

[0194] 1 H NMR (600 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.99 (s, 1H), 8.67 (d, J = 5.2 Hz, 1H), 8.60 (s, 1H), 8.32 (d, J = 8.1 Hz, 1H), 7.92 (d, J = 12.9 Hz, 1H), 7.64 (dd, J = 8.9, 5.1 Hz, 2H), 7.55-7.52 (m, 2H), 7.44 (t, J = 9.0 Hz, 1H), 7.16 (t, J = 8.9 Hz, 2H), 6.88 (brs, 2H), 6.49 (d, J = 5.2 Hz, 1H), 4.22 (dt, J = 13.9, 6.8 Hz, 1H), 4.02 (s, 3H), 2.90 (d, J = 6.5 Hz, 2H), 1.50-1.44 (m, 4H), 1.22 (d, J = 6.7 Hz, 3H). LCMS (ESI) m / z 590.33 [M+H] + . HPLC purity: 99.67%.

[0195] Example 9 Cbo-25

[0196] Scheme 10. Synthetic scheme for the preparation of Cbo-25 [ka]

[0197] N-(4-((6-(2-chloro-4-nitrophenoxy)-7-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (25)

[0198] To a solution of compound 18 (1 equiv.) and Cs2CO3 (2-5 equiv.) in DMF, 2-chloro-1-fluoro-4-nitrobenzene (1-2 equiv.) was added. The mixture was stirred at room temperature for 1-4 h. Water and EA were added to the mixture. The resulting solid was filtered to give compound 25 (82% yield) as a white solid.

[0199] N-(4-((6-(4-amino-2-chlorophenoxy)-7-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (Cbo-25)

[0200] A solution of compound 25 (1 equiv.) and Fe (2–5 equiv.) in EtOH was diluted with saturated NH (aq.) was added. The mixture was stirred at 70–100 °C for 1–4 h. The mixture was filtered through a Celite pad. The filtrate was diluted with EA, washed with water, then with brine, and removed H2O with Na2SO4. The mixture was filtered and concentrated to dryness. The crude product was purified by column chromatography to give Cbo-25 (yield 88%) as a beige solid.

[0201] 1 H NMR (600 MHz, DMSO-d6) δ 10.35 (s, 1H), 9.99 (s, 1H), 8.50 (d, J = 5.2 Hz, 1H), 7.85 (dd, J = 13.4, 1.8 Hz, 1H), 7.65-7.61 (m, 2H), 7.53 (s, 1H), 7.47 (d, J = 8.9 Hz, 1H), 7.35 (t, J = 9.0 Hz, 1H), 7.17-7.12 (m, 2H), 7.10 (s, 1H), 7.01 (d, J = 8.6 Hz, 1H), 6.76 (d, J = 2.6 Hz, 1H), 6.59 (dd, J = 8.6, 2.6 Hz, 1H), 6.38 (d, J = 5.2 Hz, 1H), 5.38 (s, 2H), 4.03 (s, 3H), 1.48-1.43 (m, 4H). LCMS (ESI) m / z 631.62 [M+H] + . HPLC purity: 99.26%.

[0202] Efficacy test example

[0203] Example 10 In Vitro Cytotoxicity Assay

[0204] Human breast cancer cell line MDA-MB-231 (6x10 3 ) and MDA-MB-453(2.4x10 4 ), human colorectal cancer cell line SW48 (2.4x10 4 ), human breast epithelial cell line M10 (6x10 3 ), human lung cancer cell line A549 (1.4x10 3 ), and mouse colorectal cancer tumor CT26 (6x10 3 Six different cell lines, including MDA-MB-231, MDA-MB-453, and SW48, were used and seeded in 96-well plates. The cell lines were obtained from Bioresource Collection and Research Center (BCRC), Taiwan. All cell lines were treated with compounds including the above compound series as well as cabozantinib and zanzarintinib (MCE®, Cat. No. HY-13016 and Cat. No. HY-138696) as positive controls at doses ranging from 25, 12.5, 6.25, 3.125, and 1.56 μM, and then incubated at 37° C. under 5% CO2 for 72 hours. After 72 hours, cell viability was determined using an MTT assay (Cayman™). MDA-MB-231, MDA-MB-453, and SW48 cell lines were maintained in DMEM / F12 supplemented with 10% FBS, 0.2% antibiotics (MycoZap™, Pluse-CL). M10 cell lines were maintained in MEM Alpha (Gibco™) supplemented with 10% FBS, 0.2% antibiotics (MycoZap™, Pluse-CL). CT26 cell lines were maintained in RPMI 1640 (CORNING™) supplemented with 10% FBS, 0.2% antibiotics (MycoZap™, Pluse-CL). A549 cell lines were maintained in DMEM (CORNING™) supplemented with 10% FBS, 0.2% antibiotics (MycoZap™, Pluse-CL).

[0205] Example 11 Screening method for 60 human cancer cell lines

[0206] Human tumor cell lines from a cancer screening panel are grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, cells are seeded in 100 μL into 96-well microtiter plates at a plating density of 5,000-40,000 cells / well depending on the doubling time of the individual cell line. After cell seeding, the microtiter plates are incubated at 37 °C, 5% CO2, 95% air and 100% relative humidity for 24 hours before experimental drugs are added. After 24 hours, two plates of each cell line are fixed in situ with TCA to represent a measure of the cell population of each cell line at the time of drug addition (Tz). Experimental drugs are solubilized in dimethyl sulfoxide to 400 times the desired final maximum test concentration and stored frozen prior to use. At the time of drug addition, thaw an aliquot of the frozen concentrate and dilute to twice the desired final maximum test concentration in complete medium containing 50 μg / ml gentamicin. 1 1 / 2 log serial dilutions are performed to provide a total of five drug concentrations and controls. Aliquots of 100 μl of these different drug dilutions are added to the appropriate microtiter wells already containing 100 μl of medium to yield the required final drug concentrations. After drug addition, the plates are incubated for an additional 48 h at 37°C, 5% CO2, 95% air, and 100% relative humidity. For adherent cells, the assay is terminated by the addition of cold TCA. Cells are fixed in situ by gentle addition of 50 μL of cold 50% (w / v) TCA (final concentration, 10% TCA) and incubated for 60 min at 4°C. The supernatant is discarded and the plate is washed five times with tap water and air-dried. 100 μl of 0.4% (w / v) sulforhodamine B (SRB) solution in 1% acetic acid is added to each well and the plate is incubated for 10 min at room temperature. After staining, unbound dye is removed by washing five times with 1% acetic acid and the plates are air-dried. Bound stain is then solubilized with 10 mM Trizma base and absorbance is read on an automated plate reader at a wavelength of 515 nm. For suspension cells, the methodology is the same, except that the assay is terminated by fixing stationary cells to the bottom of the wells by gently adding 50 μl of 80% TCA (final concentration, 16% TCA).

[0207] Example 12 Tyrosine Kinase Inhibition Assay

[0208] Tyrosine kinase inhibition assays were performed using standard protocols (SelectScreen Biochemical Profiling Service, Thermo Fisher Scientific) at ThermoFisher Life Technologies (Madison, WI, USA). The ATP concentration used was the apparent Km. Test compounds were screened in 1% dimethyl sulfoxide (DMSO) (final concentration) in the wells. For 10-point titrations, 3-fold serial dilutions were performed from a starting concentration of 10 μM. All peptide / kinase mixtures were diluted to 2x working concentration in the appropriate kinase buffer. All ATP solutions were diluted to 4x working concentration in kinase buffer (50 mM HEPES pH 7.5, 0.01% BRIJ®-35, 10 mM MgCl2, 1 mM EGTA). The apparent ATP Km was previously determined using the Z'-LYTE assay. The color reagent was diluted in color development buffer.

[0209] Example 13 Cell lines and cell culture for animal testing

[0210] LLC1 and CT26 were obtained from Bioresource Collection and Research Center (BCRC, Taiwan). LLC1 was grown in DMEM (No. 10-013-CM, Corning®) containing 10% heat-inactivated fetal bovine serum and 1× MycoZap antibiotic at 37°C under humidified air with CO2. CT26 was grown in RPMI1640 (Cat. No. 10-040-CM, Corning®) containing 10% heat-inactivated fetal bovine serum and 1× MycoZap antibiotic at 37°C under humidified air with CO2. After the cancer cell culture was completed, it was transplanted into the back of the mouse for growth (1×10 6 cells / mouse).

[0211] Example 14 Experimental Tumor Models and Treatment Methods

[0212] Animal experiments were approved and supervised by the Taipei Medical University Animal Care and Use Committee (TMU IACUC, NO: LAC-2022-0197 and LAC-2022-0306). For all animal experiments, 6- to 8-week-old male Balb / c mice (National Laboratory Animal Center, Taiwan) were used. Tumors were cultured at 1 × 10 6 CT26 cells were established by subcutaneous (sc) injection into the left flank of mice with Matrigel (354248, Corning®) and growth was determined by measuring two perpendicular diameters. Tumors were grown for 10-12 days (tumor size approximately 250-300 mm) prior to randomization and treatment. 3 The tumor volumes of the mice were measured once every 3 or 4 days (twice a week). 3When the schizophrenia score reached 1.0, the animals were euthanized. Cabozantinib (HY-13016, MedChemExpress, USA), regorafenib (HY-10331, MedChemExpress, USA), chidamide-K30, GNTbm-38-K30, GNTbm-38-HCL, Cbo-02, Cbo-20, Cbo-22, Cbo-23, and Cbo-24 were orally administered once daily for 12 or 16 days. Cabozantinib, regorafenib, Cbo-02, Cbo-20, Cbo-22, Cbo-23, and Cbo-24 were dissolved in DMSO and diluted with water before administration (final concentration of DMSO, 5% v / v). Cbo-23-K30, chidamide-K30 and GNTbm-38-K30 were directly dissolved in water and then administered. Relapse / recurrence was defined as the reappearance of tumor growth in mice with CR or PR response after secondary tumor evaluation, and tumor size reached at least 5-fold. In this study, we defined complete response (CR, <0.5-fold tumor growth in tumor-bearing mice at tumor evaluation after the end of treatment); partial response (PR, ≥0.5-fold tumor growth in tumor-bearing mice at tumor evaluation after the end of treatment, but <1-fold tumor growth); stable disease (SD, ≥1-fold tumor growth in tumor-bearing mice at tumor evaluation after the end of treatment, but <5-fold tumor growth); and progressive disease (PD, ≥5-fold tumor growth in tumor-bearing mice at tumor evaluation after the end of treatment) for evaluation of therapeutic efficacy.

[0213] Example 15 Tumor rechallenge test

[0214] Mice scored as CR / PR could participate in the rechallenge study. All mice with PR / CR responses underwent rechallenge with CT26 cells on the contralateral side. The first rechallenge consisted of 1 × 10 cells per mouse after the second evaluation. 6Tumor doses of 1000 x 1000 cells were used. After 7 days of growth, CT26 and LLC1 tumor sizes were used as baseline. Tumor growth was monitored for 11 days, with tumor size assessments against baseline performed on day 11. A response was considered a recurrence if both of the following criteria were met: first, tumor size was more than 1.5-fold compared to baseline tumor size; second, tumor volume was greater than 150 mm 3 It exceeded that.

[0215] result

[0216] Tables 1-8 referred to herein are provided below:

[0217] [ka]

[0218] [Table 1]

[0219] [Table 2]

[0220] [Table 3] TIFF2025069098000038.tif204160

[0221] [Table 4] TIFF2025069098000040.tif211160

[0222] [Table 5] TIFF2025069098000042.tif214160

[0223] [Table 6] TIFF2025069098000044.tif175169

[0224] [Table 7]

[0225] [Table 8] TIFF2025069098000047.tif125169

[0226] [Table 9] TIFF2025069098000049.tif141169

[0227] Synthesis of various kinase inhibitors with novel structures and potent immunomodulatory activities.

[0228] An immune-competent mouse animal testing platform was used to screen compounds and evaluate their immune-modulating activity. These structurally similar compounds were tested for anti-cancer activity in in vivo tests by monotherapy or combination therapy, where it was demonstrated that anti-cancer activity was achieved by selectively attacking tumors and generating immune memory through the mechanism of cancer immunotherapy. In this disclosure, the inventors focused on the mechanism of these orally available and potently immune-modulating multikinase inhibitors, especially in combination with specific HDAC inhibitors, which can significantly inhibit tumor growth. The inventors demonstrated that this anti-cancer mechanism correlates with the mechanism of cancer immunotherapy. All novel compounds were confirmed for their chemical structure by NMR and mass spectrometry, and then subjected to a series of cell proliferation and enzyme activity inhibition assays, as well as animal tests. In this disclosure, three well-known multikinase inhibitors (cabozantinib, zanzarintinib, and regorafenib) are specifically used as positive controls. Simultaneously, two unique HDAC inhibitors (chidamide / tucidinostat and GNTbm-38) were also used to combine the new compounds to confirm their unique anti-cancer immunotherapy activity. The synthetic routes, conditions, and spectroscopic data of all novel compounds can be found in the Materials and Methods section.

[0229] The newly synthesized compounds have been shown to inhibit the proliferation of various cancer cell lines.

[0230] As shown in Table 2, four human cancer cell lines (MDA-MB-453, MDA-MB-231, SW48 and A549), as well as one human normal cell line (M10) and a mouse colorectal cancer cell line (CT-26) were tested for growth inhibition after treatment with these compounds. Many of the novel compounds showed better growth inhibition activity against these cancer cell lines when compared to two positive controls (cabozantinib and zanzarintinib), such as Cbo-02, Cbo-05, Cbo-07, Cbo-08, Cbo-10, Cbo-14, Cbo-20 and Cbo-23. Furthermore, as shown in Tables 3, 4 and 5, Cbo-02, Cbo-10 and Cbo-23 were tested on NCI-60 human cancer cell lines for growth inhibition analysis, and the GI of these compounds was evaluated. 50 Compounds with potent in vitro anticancer activity were further screened for inhibitory activity against tyrosine kinases and analyzed for anticancer activity by in vivo animal testing. Cabozantinib was used as a positive control for these analyses. As shown in Table 6, Cbo-02, Cbo-10, Cbo-14, and Cbo-23 were tested for tyrosine kinase enzyme inhibitory activity to determine whether there were differences in the tyrosine kinase inhibition profile.

[0231] In vitro tyrosine kinase inhibition profiles of Cbo-02, Cbo-10, Cbo-14, and Cbo-23.

[0232] To determine the selective inhibitory activity of a given compound against various tyrosine kinases, the SelectScreen Kinase Profiling Service from ThermoFisher was used. Multiple potential compounds, such as Cbo-02, Cbo-10, Cbo-14, and Cbo-23, were further entered into the tyrosine kinase enzyme platform for inhibitory activity assays. The data was determined using the SelectScreen Biochemical Kinase Profiling Service and performed at Thermo Fisher Life Technologies. The inhibitory activity of the compounds was determined in a biochemical assay using a single concentration (1.0 μM) measurement. The results were presented as percent inhibition values. Compounds showing percent inhibition values ​​of more than 80% were defined as hits. 99 different tyrosine kinases were used, and the list of kinases for each of these panels is shown in Table 6. Among the above compounds, the most notable is Cbo-23, which has been shown to have a similar inhibitory tyrosine kinase profile as cabozantinib, suggesting that inhibition may be primarily correlated with inhibition of tumor progression, inhibition of angiogenesis, inhibition of tumor invasion, and inhibition of tumor metastasis. As shown in Table 6, the differences in the profiles may suggest that Cbo-23 has immune-modulating activity within the tumor microenvironment. Interestingly, Cbo-23 significantly inhibits more than 20 kinase targets, including AXL, BTK, CSF1R, FGR, FLT3, FLT4, KDR (VEGFR2), c-MER, c-MET, RON, PDGFR-A, RET, ROS-1, SRC, TEK (Tie-2), TYRO3, FER, FRK, HCK, INSRR, LCK, TYN-A / -B, MST1R, NTRK-2, EPHA, EPHB, and YES1. As shown in Table 7, the inhibition of the enzyme activity of Cbo-23 in 16 types of tyrosine kinases, including MERTK (c-MER), ROS1, BTK, NTRK2 (TRKB), LYNB, FLT4 (VEGFR3), EPHA2, HCK, FER, FGR, SRC, PDGFRA, MST1R (RON), LYNA, INSRR (IRR), and TEK (Tie-2), was significantly stronger than that of cabozantinib and zanzarintinib.There are several important tyrosine kinase targets, and Cbo-23, although not significantly superior to cabozantinib and zanzarintinib, also has very strong inhibitory activity against kinases such as AXL, TYRO3 (RSE), LCK, FLT3, FRK (PTK5), RET, KDR (VEGFR2), and MET (c-MET). From the above results, it is clear that Cbo-23 is a very promising multikinase inhibitor with immunomodulatory activity.

[0233] Therapeutic response of Cbo-02 in combination with chidamide-K30 in CT26 tumor-bearing mice.

[0234] After confirmation of multiple kinase inhibitory activity, the compounds were evaluated for in vivo anti-cancer activity by using immune-competent cancer-burdened mice, and CT-26 cold tumor cancer cell line was selected as a stringent test for evaluation of tumor growth inhibition. As shown in Figure 2A, the timing of compound administration was carefully designed along with efficacy and survival rate evaluation. For evaluation, both monotherapy and combination therapy were tested for tumor growth inhibition, as shown in Figure 2B and Figure 2C, respectively. The anti-cancer activity of the combination of cabozantinib and chidamide-K30 is significantly superior to that of the combination of Cbo-02 and chidamide-K30, and appears to be superior to any monotherapy treatment. In addition to these monotherapy anti-cancer effects, we are particularly interested in the regulatory mechanism of multi-kinase inhibitors when combined with special HDAC inhibitors, suggesting significantly superior immune-modulating activity within the tumor microenvironment, which can significantly inhibit tumor growth and obtain high ORR. As shown in Figure 2E, when combined with chidamide-K30 (HDAC inhibitor), the results show that the effect of treatment with cabozantinib (30 mg / kg, as a positive control) + chidamide-K30 (50 mg / kg) (ORR = 60%) > the effect of treatment with Cbo-02 (30 mg / kg) + chidamide-K30 (50 mg / kg) (ORR = 30%) > the effect of treatment with chidamide-K30 (50 mg / kg) (ORR = 11%) > the effect of treatment with Cbo-02 (30 mg / kg) (ORR = 10%) > the effect of treatment with cabozantinib (30 mg / kg) (ORR = 0%). The results clearly showed that Cbo-02 combined with chidamide-K30 has an additive anticancer effect, while cabozantinib combined with chidamide-K30 appears to have a synergistic anticancer effect. The survival data also showed that the anticancer activity of cabozantinib combined with chidamide-K30 was significantly better than that of Cbo-02 combined with chidamide-K30, as shown in Figure 2F. Although the combination of cabozantinib and chidamide-K30 had superior anticancer effect, it was found to have a higher tumor recurrence rate after treatment cessation, as shown in Figure 2G.Body weight showed little change after treatment with the compound or drug was stopped, and no significant difference occurred, as shown in FIG. 2D.

[0235] Therapeutic response of Cbo-20 in combination with GNTbm-38-K30 in CT26 tumor-bearing mice.

[0236] The in vivo study design is shown in Figure 3A. All compounds or drugs were orally administered for 12 days, followed by evaluation of tumor inhibition growth 10 days after treatment cessation, during which tumor size was measured twice a week, as shown in Figure 3B and Figure 3C. Monotherapy with Cbo-20 has better anticancer activity than monotherapy with cabozantinib. However, in terms of combination therapy, Cbo-20 combined with GNTbm-38 was similar to cabozantinib combined with GNTbm-38, both of which showed extremely good anticancer activity, as shown in Figure 3B and 3C. As shown in FIG. 3E, the fold change in individual tumor size and ORR were as follows: GNTbm-38-K30 (40 mg / kg) group achieved 0 CR, 0 PR, 1 SD, and 5 PD, with an ORR of 0%; cabozantinib (30 mg / kg) group achieved 0 CR, 0 PR, 2 SD, and 5 PD, with an ORR of 0%; Cbo-20 (30 mg / kg) group achieved 2 CR, 2 PR, 2 SD, and 2 PD, with an ORR of 50%; cabozantinib (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) group achieved 5 CR, 1 PR, 1 SD, and 2 PD. The Cbo-20 (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) arm achieved 6 CR, 1 PR, 1 SD, and 0 PD with an ORR of 88%. These results indicate that Cbo-20 in combination with GNTbm-38 is similar to cabozantinib in combination with GNTbm-38, both of which showed significantly better ORR. The results show that treatment with Cbo-20 (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) (ORR = 88%) > treatment with cabozantinib (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) (ORR = 86%) > treatment with Cbo-20 (30 mg / kg) (ORR = 50%) > treatment with cabozantinib (30 mg / kg) (ORR = 0%) = treatment with GNTbm-38-K30 (40 mg / kg) group (ORR = 0%).

[0237] As shown in Figure 3F, the analysis of survival rates showed that the combination of Cbo-20 in combination with GNTbm-38 was slightly superior to the combination of cabozantinib in combination with GNTbm-38, with the results being Cbo-20 (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) (survival rate = 88%) > cabozantinib (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) (survival rate = 71%) > Cbo-20 (30 mg / kg) (survival rate = 25%) > GNTbm-38-K30 (40 mg / kg) group (survival rate = 16%) > cabozantinib (30 mg / kg) group (survival rate = 0%). The recurrence rate was evaluated as shown in Figure 3G. Only in the Cbo-20 (30 mg / kg) group, 3 mice with tumor recurrence (recurrence rate = 75% (3 / 4)) were observed, while the other two combination groups did not show any recurrence at day 60. This also indicates that these two combinations are superior in preventing cancer recurrence. As shown in Figure 3D, after all treatments alone or in combination, the weight of the mice did not change much and no significant changes occurred. To further evaluate whether immune memory is induced, a rechallenge test was used for evaluation. As shown in Table 8, the combination of Cbo-20 and GNTbm-38 significantly inhibited tumor growth and significantly induced immune memory. In the rechallenge test, two tumors were separately implanted into the back of mice along with two different cancer cell lines, which had CR and PR responses after treatment. These two cancer cell lines were CT-26, which was induced to be recognized by the immune system during treatment, and LLC-1 cell line, which was not induced to be recognized by the immune system during treatment. Thus, CT-26 tumors did not grow, whereas LLC1 tumors grew significantly.

[0238] Therapeutic response of Cbo-22 in combination with GNTbm-38-K30 in CT26 tumor-bearing mice.

[0239] As shown in Figures 4A and 4B, the tumor-inhibiting activity of Cbo-22 was tested in CT-26-bearing mice using monotherapy or combination therapy with GNTbm-38. The anti-cancer activity of cabozantinib in combination with GNTbm-38 was significantly superior to the anti-cancer activity of Cbo-22 in combination with GNTbm-38. This combination was significantly superior to other treatments, as shown in Figures 4A and 4B. The results, as shown in Figure 4D, indicate that treatment with cabozantinib (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) (ORR = 86%) > treatment with Cbo-22 (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) (ORR = 25%) > treatment with Cbo-22 (30 mg / kg) (ORR = 0%) = treatment with cabozantinib (30 mg / kg), and the synergistic anticancer effect of cabozantinib in combination with GNTbm-38 was significantly superior to the combination regimen of Cbo-22 and GNTbm-38. The overall survival rate is shown in Figure 4E, where the cabozantinib (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) group (survival rate = 71%) > Cbo-22 (30 mg / kg) + GNTbm-38-K30 (40 mg / kg) group (survival rate = 25%) > GNTbm-38-K30 (40 mg / kg) group (survival rate = 16%) > cabozantinib (30 mg / kg) group (survival rate = 0%) > Cbo-22 (30 mg / kg) group (survival rate = 0%). The recurrence rate was evaluated as shown in Figure 4F. The recurrence rate results showed that there was no recurrence in these two combination groups. The treatment did not cause significant differences in body weight, as shown in Figure 4C.

[0240] Therapeutic response of Cbo-23 in combination with GNTbm-38-K30 in CT26 tumor-bearing mice.

[0241] The animal test scheme is shown in Figure 5A. In addition to cabozantinib, it was recognized that regorafenib, a multi-kinase inhibitor, also showed similar immunomodulatory activity compared with cabozantinib. Therefore, in this animal experiment, regorafenib was specifically used as a positive control. As shown in Figure 5B and Figure 5C, Cbo-23 combined with GNTbm-38 is superior to regorafenib combined with GNTbm-38 in inhibiting tumor growth. As shown in Figure 5D, after all treatments, monotherapy or combination therapy, the weight of mice did not change significantly. As shown in Figure 5E, the results indicate that treatment with Cbo-23 (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) (ORR = 89%) > treatment with regorafenib (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) (ORR = 56%) > treatment with GNTbm-38-K30 (5 mg / kg) (ORR = 25%) > treatment with Cbo-23 (30 mg / kg) (ORR = 22%) > treatment with regorafenib (30 mg / kg) (ORR = 0%). As shown in FIG. 5E, the fold change in individual tumor size and ORR were as follows: GNTbm-38-K30 (5 mg / kg) group achieved 1 CR, 1 PR, 0 SD, and 6 PD, with an ORR of 25%; regorafenib (30 mg / kg) group achieved 0 CR, 0 PR, 2 SD, and 7 PD, with an ORR of 0%; Cbo-23 (30 mg / kg) group achieved 2 CR, 0 PR, 0 SD, and 7 PD, with an ORR of 22%; and regorafenib (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group achieved 5 CR, 0 PR, 3 SD, and 7 PD, with an ORR of 25%. The Cbo-23 (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group achieved 8 CR, 0 PR, 0 SD, and 1 PD, with an ORR of 89%. These results demonstrate that Cbo-23 combined with GNTbm-38 has excellent anticancer effects, and Cbo-23 is a highly promising multikinase inhibitor with immunomodulatory activity.Overall survival is shown in Figure 5F, where Cbo-23 (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group (survival rate = 89%) > Regorafenib (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group (survival rate = 67%) > GNTbm-38-K30 (5 mg / kg) group (survival rate = 13%) > Cbo-23 (30 mg / kg) group (survival rate = 11%) > Regorafenib (30 mg / kg) group (survival rate = 0%). Recurrence rates were evaluated as shown in Figure 5G. The results of the recurrence rate showed that the GNTbm-38-K30 (5 mg / kg) group had one recurrence mouse (recurrence rate = 50% (1 / 2)), the Cbo-23 (30 mg / kg) group had one recurrence mouse (recurrence rate = 50% (1 / 2)), the Cbo-23 (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group had one recurrence mouse (recurrence rate = 13% (1 / 8)), and the regorafenib (30 mg / kg) + GNTbm-38-K30 group had no recurrence mice on day 60. Whether immune memory is induced or not To further confirm whether or not the rechallenge was successful, a rechallenge study was performed as shown in Table 9. We were intrigued that Cbo-23 in combination with GNTbm-38 demonstrated induction of immune memory, as evidenced by LLC1 tumor growth in parallel with inhibition of CT-26 tumor growth. This indeed demonstrated that Cbo-23 in combination with GNTbm-38 is a potent regimen that can activate the immune system, selectively attack tumors, and generate immune memory, as shown in Table 9.

[0242] Therapeutic response of Cbo-23 compared to cabozantinib, monotherapy, or combination therapy in CT26 tumor-bearing mice

[0243] Cabozantinib, a multi-kinase inhibitor, is known to exhibit immunomodulatory activity. Therefore, an animal experiment was designed to compare the immunomodulatory activity between Cbo-23 and cabozantinib. The animal experiment scheme is shown in Figure 6A. As shown in Figure 6B and Figure 6C, the activity of Cbo-23 combined with GNTbm-38 is superior to the activity of cabozantinib combined with GNTbm-38 in inhibiting tumor growth. After all treatments, monotherapy or combination therapy, the body weight of the mice did not change significantly, as shown in Figure 6D. The results, as shown in Figure 6E, indicate that treatment with Cbo-23 (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) (ORR = 90%) > treatment with cabozantinib (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) (ORR = 70%) > treatment with cabozantinib (30 mg / kg) (ORR = 44%) > treatment with Cbo-23 (30 mg / kg) (ORR = 30%) > treatment with GNTbm-38-K30 (20 mg / kg) (ORR = 25%). The fold change in individual tumor size and ORR are shown in FIG. 6E. The GNTbm-38-K30 (20 mg / kg) group achieved 2 CRs, 0 PRs, 0 SDs, and 6 PDs, with an ORR of 25%; the cabozantinib (30 mg / kg) group achieved 3 CRs, 1 PR, 3 SDs, and 2 PDs, with an ORR of 44%; the Cbo-23 (30 mg / kg) group achieved 3 CRs, 0 PRs, 0 SDs, and 7 PDs, with an ORR of 30%; and the cabozantinib (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group achieved 6 CRs, 1 PR, 1 SD, and 2 PDs. The Cbo-23 (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group achieved 9 CR, 0 PR, 0 SD, and 1 PD, with an ORR of 90%. These results demonstrate that Cbo-23 combined with GNTbm-38 has excellent anticancer effects, and Cbo-23 is a highly promising multikinase inhibitor with immunomodulatory activity.Overall survival rates are shown in Figure 6F, where Cbo-23 (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group (survival rate = 90%) > cabozantinib (30 mg / kg) + GNTbm-38-K30 (20 mg / kg) group (survival rate = 70%) > cabozantinib (30 mg / kg) (survival rate = 33%) > GNTbm-38-K30 (20 mg / kg) group (survival rate = 25%) > Cbo-23 (30 mg / kg) group (survival rate = 20%). Recurrence rates were evaluated as shown in Figure 6G.

[0244] Therapeutic response of Cbo-23-K30 in combination with GNTbm-38-2HCL in CT26 tumor-bearing mice.

[0245] Zanzarintinib, a new generation multikinase inhibitor, is also known to exhibit immunomodulatory activity. Based on the salt form of Zanzarintinib (Zanzarintinib hemifumarate), Cbo-23 was formulated into a fumarate salt form and also into an amorphous solid dispersion (ASD) in PVP K-30 to enhance the solubility and bioavailability of Cbo-23. As shown in Figure 7A, the initial tumor size before treatment was 263.9 mm 3Therefore, in this animal experiment, zanzarintinib hemifumarate was specifically used as a positive control. As shown in Figure 7B and Figure 7C, the tumor inhibition rates of the single agent zanzarintinib hemifumarate (30 mg / kg) group and the Cbo-23-K30 (30 mg / kg) group on day 28 were 2% and 22%, respectively. The activity of Cbo-23-K30 (30 mg / kg) in combination with GNTbm-38-2HCL (40 mg / kg) was superior to that of zanzarintinib hemifumarate (30 mg / kg) in combination with GNTbm-38-2HCL (40 mg / kg) in inhibiting tumor growth, with tumor inhibition rates of 87% and 76%, respectively, on day 28. As shown in Figure 7D, the body weight of the mice did not change significantly after all treatments, either single agent or combination therapy. The results, as shown in Figure 7E, indicate that treatment with Cbo-23-K30 (30 mg / kg) + GNTbm-38-2HCL (40 mg / kg) (ORR = 66.6%) > treatment with zanzarintinib hemifumarate (30 mg / kg) + GNTbm-38-2HCL (40 mg / kg) (ORR = 0%). The fold change in individual tumor size and ORR are shown in FIG. 7E. The GNTbm-38-2HCL (40 mg / kg) group achieved 0 CR, 0 PR, 0 SD, and 9 PD cases, with an ORR of 0%; the zanzarintinib hemifumarate (30 mg / kg) group achieved 0 CR, 0 PR, 0 SD, and 9 PD cases, with an ORR of 0%; the Cbo-23-K30 (30 mg / kg) group achieved 0 CR, 0 PR, 0 SD, and 9 PD cases, with an ORR of 0%; and the zanzarintinib hemifumarate (30 mg / kg) + GNTbm-38-2HCL (40 mg / kg) group achieved 0 CR, 0 PR, 2 SD, and 9 PD cases, with an ORR of 0%. The Cbo-23-K30 (30mg / kg) + GNTbm-38-2HCL (40mg / kg) group achieved 4 CR, 2 PR, 1 SD, and 2 PD, with an ORR of 66.6%. These results demonstrate that the combination of Cbo-23-K30 and GNTbm-38-2HCL has excellent anticancer effects through a synergistic mechanism.Cbo-23 is a highly promising multikinase inhibitor with immune-modulating activity. Overall survival is shown in Figure 7F, where Cbo-23-K30 (30 mg / kg) + GNTbm-38-2HCL (40 mg / kg) group (survival rate = 77.7%) > Zanzarintinib hemifumarate (30 mg / kg) + GNTbm-38-2HCL (40 mg / kg) group (survival rate = 0%). In the analysis of OS at day 61, it can be observed that there are still 3 CR cases in the Cbo-23-K30 combination group, which indicates that the Cbo-23-K30 combination group has significant tumor immune activation ability compared with the Zanzarintinib hemifumarate combination group. The recurrence rate was evaluated as shown in Figure 7G.

[0246] It should be understood that those skilled in the art of the subject disclosure may make changes and modifications to the teachings and disclosures of the application disclosure without departing from the spirit and scope of the subject application. Based on the above, it is intended that the subject application encompasses any such changes and modifications, provided that such changes or modifications fall within the scope defined in the appended claims or their equivalents.

Claims

1. Formula (I): 【Chemistry 1】 (In the formula: A is -OD or 【Chemistry 2】 where the wavy lines represent the bond positions; D is H, C 1-4 alkyl or Ar; Ar is 【Chemistry 3】 where the dashed line represents the bond position; X is N, CH or CR d n is an integer from 0 to 3; Each R d is, if present, methyl, NH 2 , OH, SH, methoxy, dimethylamino, trifluoromethoxy, cyanide, nitro, nitroso, sulfonate, sulfonamide, C 1 -C 6 Alkyl, C 1 -C 6 independently selected from the group consisting of alkyloxy, carboxamido, F, Cl, and Br; R p is H, methyl, NH 2 , OH, SH, methoxy, dimethylamino, trifluoromethoxy, cyanide, nitro, nitroso, sulfonate, sulfonamide, C 1 -C 6 Alkyl, C 1 -C 6 selected from the group consisting of alkyloxy, carboxamido, F, Cl and Br; L 1 , L 2 is (i) -NH-C(=O)- or (ii) -(C=O)-NH-; and L 3 , L 4 is (i) -NH-C(=O)- or (ii) -(C=O)-NH-. or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

2. Formula (II): 【Chemistry 4】 (In the formula, D, L 1 , L 2 , L 3 and L 4 has the same meaning as described in formula (I).

2. The compound of claim 1 having the formula:

3. Formula (III): 【Chemistry 5】 (In the formula, D, L 3 and L 4 has the same meaning as described in formula (I).

2. The compound of claim 1 having the formula:

4. Formula (IV): 【Chemistry 6】 (wherein D has the same meaning as described in formula (I)).

2. The compound of claim 1 having the formula:

5. Ar 【Chemistry 7】 and X is N, CH or CR o and R p But, H, NH 2 and nitro; Each R m H, methyl, NH 2 , nitro, nitroso, sulfonate, sulfonamide, C 1 -C 6 Alkyl, C 1 -C 6 independently selected from the group consisting of alkyloxy, carboxamido, F, Br, and Cl; Each R o H, methyl, NH 2 , nitro, nitroso, sulfonate, sulfonamide, C 1 -C 6 Alkyl, C 1 -C 6 independently selected from the group consisting of alkyloxy, carboxamide, F, Br and Cl; 2. The compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

6. Ar, 【Chemistry 8】 and X is N, CH or CR o and R p But, H, NH 2 and nitro; Each R o H, methyl, NH 2 , nitro, nitroso, sulfonate, sulfonamide, C 1 -C 6 Alkyl, C 1 -C 6 independently selected from the group consisting of alkyloxy, carboxamide, F, Br and Cl; 6. The compound of claim 5 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

7. Ar, 【Chemistry 9】 【change】 2. The compound of claim 1 selected from the group consisting of: or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

8. below: 【Chemistry 10】 【change】 2. The compound of claim 1 selected from the group consisting of: or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

9. 10. A pharmaceutical composition or combination comprising a compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof, and a pharma- ceutically acceptable carrier.

10. 10. The pharmaceutical composition or pharmaceutical combination of claim 9, further comprising one or more second agents.

11. The pharmaceutical composition or pharmaceutical combination according to claim 10, wherein the second agent is an immune checkpoint inhibitor, an anticancer agent, or a combination thereof.

12. 13. A method for inhibiting angiogenesis in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

13. 13. A method for inhibiting metastasis in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate, or prodrug thereof.

14. 13. A method for inhibiting carcinogenesis in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

15. A method for regulating immunomodulatory activity in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

16. 13. A method for treating or preventing a disease associated with tyrosine kinase (TK) in a subject in need thereof, comprising administering to the subject an effective amount of a compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

17. 13. A method for treating a tumor or cancer in a subject in need thereof, comprising administering to the subject an effective amount of the compound of claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

18. 18. The method of claim 17, wherein the method comprises cancer immunotherapy by modulating the tumor microenvironment, reducing tumor hypoxia, reducing lactate accumulation, activating CTLs, suppressing the number and activity of immunosuppressive cells, obtaining better anti-cancer effects and / or inducing durable immune memory.

19. 10. A method for treating a tumor or cancer with an enhanced objective response rate (ORR) compared to tumor or cancer treatments based on pharmaceutical compositions or pharmaceutical combinations comprising conventional tyrosine kinase (TK) inhibitors, comprising administering to the subject an effective amount of a compound according to claim 1 or a pharma- ceutically acceptable salt, hydrate, stereoisomer, solvate or prodrug thereof.

Images